10-Q 1 cvs-20180930x10q.htm 10-Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10‑Q

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2018

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number 001‑01011

CVS HEALTH CORPORATION

(Exact name of registrant as specified in its charter)

Delaware | 05‑0494040
(State of Incorporation) | (I.R.S. Employer Identification Number)

One CVS Drive, Woonsocket, Rhode Island 02895

(Address of principal executive offices)

Registrant’s telephone number, including area code: (401) 765‑1500

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S‑T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

Large accelerated filer ☒ |  | Accelerated filer ☐
Non-accelerated filer ☐ |  | Smaller reporting company ☐
|  | Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Common Stock, $0.01 par value, issued and outstanding at October 31, 2018:

1,018,799,080 shares

Table of Contents

INDEX

|  | Page
Part I |  |
Item 1. | Financial Statements | 3
| Condensed Consolidated Statements of Operations (Unaudited) – Three and Nine Months Ended September 30, 2018 and 2017 | 3
| Condensed Consolidated Statements of Comprehensive Income (Unaudited) – Three and Nine Months Ended September 30, 2018 and 2017 | 4
| Condensed Consolidated Balance Sheets (Unaudited) – As of September 30, 2018 and December 31, 2017 | 5
| Condensed Consolidated Statements of Cash Flows (Unaudited) – Nine Months Ended September 30, 2018 and 2017 | 6
| Notes to Condensed Consolidated Financial Statements (Unaudited) | 7
| Report of Independent Registered Public Accounting Firm | 31
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 32
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 49
Item 4. | Controls and Procedures | 50
Part II |  | 51
Item 1. | Legal Proceedings | 51
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 51
Item 6. | Exhibits | 52
Signatures | 53

Table of Contents

Part I | Item 1

CVS Health Corporation

Condensed Consolidated Statements of Operations

(Unaudited)

|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
In millions, except per share amounts |  | 2018 |  | 2017 |  | 2018 |  | 2017
Net revenues |  | $ | 47,269 |  | $ | 46,181 |  | $ | 139,670 |  | $ | 136,380
Cost of revenues |  |  | 39,941 |  |  | 39,064 |  |  | 118,282 |  |  | 115,766
Gross profit |  |  | 7,328 |  |  | 7,117 |  |  | 21,388 |  |  | 20,614
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  | — |  |  | — |  |  | 3,921 |  |  | 135
Other operating expenses |  |  | 4,975 |  |  | 4,618 |  |  | 14,755 |  |  | 14,070
Operating profit |  |  | 2,353 |  |  | 2,499 |  |  | 2,712 |  |  | 6,409
Interest expense, net |  |  | 453 |  |  | 245 |  |  | 1,401 |  |  | 744
Other expense |  |  | 1 |  |  | 192 |  |  | 7 |  |  | 206
Income before income tax provision |  |  | 1,899 |  |  | 2,062 |  |  | 1,304 |  |  | 5,459
Income tax provision |  |  | 509 |  |  | 777 |  |  | 1,478 |  |  | 2,115
Income (loss) from continuing operations |  |  | 1,390 |  |  | 1,285 |  |  | (174) |  |  | 3,344
Loss from discontinued operations, net of tax |  |  | — |  |  | — |  |  | (1) |  |  | (8)
Net income (loss) |  |  | 1,390 |  |  | 1,285 |  |  | (175) |  |  | 3,336
Net income attributable to noncontrolling interests |  |  | — |  |  | — |  |  | — |  |  | (1)
Net income (loss) attributable to CVS Health |  | $ | 1,390 |  | $ | 1,285 |  | $ | (175) |  | $ | 3,335
Basic earnings (loss) per share: |  |  |  |  |  |  |  |  |  |  |  |
Income (loss) from continuing operations attributable to CVS Health |  | $ | 1.36 |  | $ | 1.26 |  | $ | (0.17) |  | $ | 3.26
Loss from discontinued operations attributable to CVS Health |  | $ | — |  | $ | — |  | $ | — |  | $ | (0.01)
Net income (loss) attributable to CVS Health |  | $ | 1.36 |  | $ | 1.26 |  | $ | (0.17) |  | $ | 3.25
Weighted average shares outstanding |  |  | 1,020 |  |  | 1,016 |  |  | 1,018 |  |  | 1,022
Diluted earnings (loss) per share: |  |  |  |  |  |  |  |  |  |  |  |
Income (loss) from continuing operations attributable to CVS Health |  | $ | 1.36 |  | $ | 1.26 |  | $ | (0.17) |  | $ | 3.25
Loss from discontinued operations attributable to CVS Health |  | $ | — |  | $ | — |  | $ | — |  | $ | (0.01)
Net income (loss) attributable to CVS Health |  | $ | 1.36 |  | $ | 1.26 |  | $ | (0.17) |  | $ | 3.24
Weighted average shares outstanding |  |  | 1,022 |  |  | 1,020 |  |  | 1,018 |  |  | 1,026
Dividends declared per share |  | $ | 0.50 |  | $ | 0.50 |  | $ | 1.50 |  | $ | 1.50

See accompanying notes to condensed consolidated financial statements.

3

Table of Contents

CVS Health Corporation

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)

|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
In millions |  | 2018 |  | 2017 |  | 2018 |  | 2017
Net income (loss) |  | $ | 1,390 |  | $ | 1,285 |  | $ | (175) |  | $ | 3,336
Other comprehensive income (loss): |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustments, net of tax |  |  | (8) |  |  | 8 |  |  | (34) |  |  | 6
Net cash flow hedges, net of tax |  |  | (4) |  |  | — |  |  | 335 |  |  | 1
Pension and other postretirement benefits, net of tax |  |  | — |  |  | 151 |  |  | — |  |  | 151
Total other comprehensive income (loss) |  |  | (12) |  |  | 159 |  |  | 301 |  |  | 158
Comprehensive income |  |  | 1,378 |  |  | 1,444 |  |  | 126 |  |  | 3,494
Comprehensive income attributable to noncontrolling interests |  |  | — |  |  | — |  |  | — |  |  | (1)
Comprehensive income attributable to CVS Health |  | $ | 1,378 |  | $ | 1,444 |  | $ | 126 |  | $ | 3,493

See accompanying notes to condensed consolidated financial statements.

4

Table of Contents

CVS Health Corporation

Condensed Consolidated Balance Sheets

(Unaudited)

|  | September 30, |  | December 31,
In millions, except per share amounts |  | 2018 |  | 2017
Assets: |  |  |  |  |  |
Cash and cash equivalents |  | $ | 41,587 |  | $ | 1,696
Short-term investments |  |  | 105 |  |  | 111
Accounts receivable, net |  |  | 14,837 |  |  | 13,181
Inventories |  |  | 14,818 |  |  | 15,296
Other current assets |  |  | 634 |  |  | 945
Total current assets |  |  | 71,981 |  |  | 31,229
Property and equipment, net |  |  | 10,419 |  |  | 10,292
Goodwill |  |  | 34,216 |  |  | 38,451
Intangible assets, net |  |  | 13,166 |  |  | 13,630
Other assets |  |  | 1,724 |  |  | 1,529
Total assets |  | $ | 131,506 |  | $ | 95,131
Liabilities: |  |  |  |  |  |
Accounts payable |  | $ | 8,813 |  | $ | 8,863
Claims and discounts payable |  |  | 12,348 |  |  | 10,355
Accrued expenses |  |  | 6,160 |  |  | 6,609
Short-term debt |  |  | — |  |  | 1,276
Current portion of long-term debt |  |  | 2,139 |  |  | 3,545
Total current liabilities |  |  | 29,460 |  |  | 30,648
Long-term debt |  |  | 60,747 |  |  | 22,181
Deferred income taxes |  |  | 3,052 |  |  | 2,996
Other long-term liabilities |  |  | 1,625 |  |  | 1,611
Total liabilities |  |  | 94,884 |  |  | 57,436
Shareholders’ equity: |  |  |  |  |  |
CVS Health shareholders’ equity: |  |  |  |  |  |
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding |  |  | — |  |  | —
Common stock, par value $0.01: 3,200 shares authorized; 1,717 shares issued and 1,019 shares outstanding at September 30, 2018 and 1,712 shares issued and 1,014 shares outstanding at December 31, 2017 |  |  | 17 |  |  | 17
Capital surplus |  |  | 32,360 |  |  | 32,079
Treasury stock, at cost: 697 shares at September 30, 2018 and December 31, 2017 |  |  | (37,702) |  |  | (37,765)
Shares held in trust: 1 share at September 30, 2018 and December 31, 2017 |  |  | (29) |  |  | (31)
Retained earnings |  |  | 41,843 |  |  | 43,556
Accumulated other comprehensive income (loss) |  |  | 129 |  |  | (165)
Total CVS Health shareholders’ equity |  |  | 36,618 |  |  | 37,691
Noncontrolling interests |  |  | 4 |  |  | 4
Total shareholders’ equity |  |  | 36,622 |  |  | 37,695
Total liabilities and shareholders’ equity |  | $ | 131,506 |  | $ | 95,131

See accompanying notes to condensed consolidated financial statements.

5

Table of Contents

CVS Health Corporation

Condensed Consolidated Statements of Cash Flows

(Unaudited)

|  | Nine Months Ended
|  | September 30,
In millions |  | 2018 |  | 2017
Cash flows from operating activities: |  |  |  |  |  |
Cash receipts from customers |  | $ | 132,275 |  | $ | 133,055
Cash paid for inventory and prescriptions dispensed by retail network pharmacies |  |  | (110,320) |  |  | (110,788)
Cash paid to other suppliers and employees |  |  | (12,305) |  |  | (11,230)
Interest received |  |  | 406 |  |  | 15
Interest paid |  |  | (1,759) |  |  | (869)
Income taxes paid |  |  | (1,911) |  |  | (2,040)
Net cash provided by operating activities |  |  | 6,386 |  |  | 8,143
Cash flows from investing activities: |  |  |  |  |  |
Purchases of property and equipment |  |  | (1,452) |  |  | (1,412)
Proceeds from sale-leaseback transactions |  |  | — |  |  | 265
Proceeds from sale of property and equipment and other assets |  |  | 11 |  |  | 20
Acquisitions (net of cash acquired) and other investments |  |  | (656) |  |  | (461)
Purchase of available-for-sale investments |  |  | (57) |  |  | —
Maturities of available-for-sale investments |  |  | 43 |  |  | 21
Proceeds from sale of subsidiary |  |  | 725 |  |  | —
Net cash used in investing activities |  |  | (1,386) |  |  | (1,567)
Cash flows from financing activities: |  |  |  |  |  |
Decrease in short-term debt |  |  | (1,276) |  |  | (1,764)
Proceeds from issuance of long-term debt |  |  | 39,376 |  |  | —
Repayments of long-term debt |  |  | (2,266) |  |  | —
Derivative settlements |  |  | 446 |  |  | —
Repurchase of common stock |  |  | — |  |  | (4,361)
Dividends paid |  |  | (1,528) |  |  | (1,539)
Proceeds from exercise of stock options |  |  | 214 |  |  | 314
Payments for taxes related to net share settlement of equity awards |  |  | (39) |  |  | (70)
Other |  |  | — |  |  | (1)
Net cash provided by (used in) financing activities |  |  | 34,927 |  |  | (7,421)
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  |  | — |  |  | —
Net increase (decrease) in cash, cash equivalents and restricted cash |  |  | 39,927 |  |  | (845)
Cash, cash equivalents and restricted cash at the beginning of the period |  |  | 1,900 |  |  | 3,520
Cash, cash equivalents and restricted cash at the end of the period |  | $ | 41,827 |  | $ | 2,675
Reconciliation of net income (loss) to net cash provided by operating activities: |  |  |  |  |  |
Net income (loss) |  | $ | (175) |  | $ | 3,336
Adjustments required to reconcile net income (loss) to net cash provided by operating activities: |  |  |  |  |  |
Depreciation and amortization |  |  | 1,911 |  |  | 1,857
Goodwill impairments |  |  | 3,921 |  |  | 135
Losses on settlements of defined benefit pension plans |  |  | — |  |  | 187
Stock-based compensation |  |  | 172 |  |  | 173
Deferred income taxes and other noncash items |  |  | 296 |  |  | 271
Change in operating assets and liabilities, net of effects from acquisitions: |  |  |  |  |  |
Accounts receivable, net |  |  | (1,725) |  |  | (280)
Inventories |  |  | 472 |  |  | 620
Other current assets |  |  | 116 |  |  | (212)
Other assets |  |  | (119) |  |  | (15)
Accounts payable and claims and discounts payable |  |  | 1,839 |  |  | 330
Accrued expenses |  |  | (341) |  |  | 1,670
Other long-term liabilities |  |  | 19 |  |  | 71
Net cash provided by operating activities |  | $ | 6,386 |  | $ | 8,143

See accompanying notes to condensed consolidated financial statements.

6

Table of Contents

CVS Health Corporation

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1 – Accounting Policies

Description of business

CVS Health Corporation and its subsidiaries (collectively, “CVS Health” or the “Company”) together comprise the largest integrated pharmacy health care provider in the United States based upon revenues and prescriptions filled. The Company currently has three reportable business segments, Pharmacy Services, Retail/LTC and Corporate, which are described below.

Pharmacy Services Segment (the “PSS”) - The PSS provides prescription drugs to plan members through mail order pharmacies, specialty pharmacies and a national network of retail pharmacies. Additional services are also offered to clients, including administration and formulary management, Medicare Part D services, infusion services, prescription management systems, clinical services, disease management services and medical spend management. The Company’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, Medicare Part D plans, Managed Medicaid plans, plans offered on the public and private exchanges, and other sponsors of health benefit plans and individuals throughout the United States.

As a pharmacy benefits manager, the PSS manages the dispensing of pharmaceuticals through the Company’s mail order pharmacies and national network of more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies and 27,000 independent pharmacies, to eligible members in the benefits plans maintained by the Company’s clients and utilizes its information systems to perform, among other things, safety checks, drug interaction screenings and brand to generic substitutions.

The PSS’ specialty pharmacies support individuals that require complex and expensive drug therapies. The specialty pharmacy business includes mail order and retail specialty pharmacies that operate primarily under the CVS Caremark®, Navarro® Health Services and Advanced Care Scripts TM (“ACS Pharmacy”) names. The Company also provides specialty infusion services and enteral nutrition services through Coram LLC and its subsidiaries (collectively, “Coram”).

The PSS also provides health management programs, which include integrated disease management for 19 conditions, through the Company’s AccordantCare TM rare disease management offering.

In addition, through the Company’s SilverScript Insurance Company (“SilverScript”) subsidiary, the PSS is a national provider of prescription drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program.

The PSS generates net revenues primarily by contracting with clients to provide prescription drugs to plan members. Prescription drugs are dispensed by the mail order pharmacies, specialty pharmacies and national network of retail pharmacies. Net revenues are also generated by providing additional services to clients, including administrative services such as claims processing and formulary management, as well as health care related services such as disease management.

The PSS operates primarily under the CVS Caremark® Pharmacy Services, Caremark®, CVS Caremark®, CVS Specialty®, AccordantCare TM, SilverScript®, Wellpartner®, Coram®, NovoLogix®, Navarro® Health Services and ACS Pharmacy TM names. As of September 30, 2018, the PSS operated 25 retail specialty pharmacy stores, 17 specialty mail order pharmacies, four mail order dispensing pharmacies, and 86 branches for infusion and enteral services, including approximately 68 ambulatory infusion suites and three centers of excellence, located in 42 states, Puerto Rico and the District of Columbia.

Retail/LTC Segment (the “RLS”) - The RLS sells prescription drugs and a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, seasonal merchandise, greeting cards, and photo finishing services, through the Company’s CVS Pharmacy®, CVS®, CVS Pharmacy y más®, Longs Drugs®, Navarro Discount Pharmacy® and Drogaria Onofre TM retail stores and online through CVS.com®, Navarro.com TM and Onofre.com.br TM.

7

Table of Contents

The RLS also provides health care services through its MinuteClinic® health care clinics. MinuteClinics are staffed by nurse practitioners and physician assistants who utilize nationally recognized protocols to diagnose and treat minor health conditions, perform health screenings, monitor chronic conditions and deliver vaccinations.

The RLS also has long-term care (“LTC”) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. Prior to January 2, 2018, the RLS also provided commercialization services under the name RxCrossroads® (“RxC”). See “Note 3 – Goodwill and Intangible Assets” to the condensed consolidated financial statements for a discussion of the divestiture of RxC.

As of September 30, 2018, the RLS included 9,905 retail stores (of which 8,149 were our stores that operated a pharmacy and 1,709 were our pharmacies located within Target stores) located in 49 states, the District of Columbia, Puerto Rico and Brazil operating primarily under the CVS Pharmacy®, CVS®, CVS Pharmacy y más®, Longs Drugs®, Navarro Discount Pharmacy® and Drogaria Onofre TM names, 37 onsite pharmacies primarily operating under the CarePlus CVS Pharmacy®, CarePlus® and CVS Pharmacy® names, and 1,102 retail health care clinics operating under the MinuteClinic® name (of which 1,098 were located in our retail pharmacy stores or Target stores), and our online retail websites, CVS.com®, Navarro.com TM and Onofre.com.br TM. LTC operations are comprised of 155 spoke pharmacies that primarily handle new prescription orders, of which 30 are also hub pharmacies that use proprietary automation to support spoke pharmacies with refill prescriptions. LTC operates primarily under the Omnicare® and NeighborCare® names.

Corporate Segment - The Corporate Segment provides management and administrative services to support the Company. The Corporate Segment consists of certain aspects of the Company’s executive management, corporate relations, legal, compliance, human resources, information technology and finance departments.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of CVS Health Corporation and its subsidiaries have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. In accordance with such rules and regulations, certain information and accompanying note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, although the Company believes the disclosures included herein are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in Exhibit 13 to the Company’s Annual Report on Form 10‑K for the year ended December 31, 2017 (“2017 Form 10‑K”).

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Because of the influence of various factors on the Company’s operations, including business combinations, certain holidays and other seasonal influences, net income for any interim period may not be comparable to the same interim period in previous years or necessarily indicative of income for the full year.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.

The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity’s economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary.

8

Table of Contents

Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company’s condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company.

Fair Value of Financial Instruments

The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:

| · |  | Level 1 – Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

| · |  | Level 2 – Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.

| · |  | Level 3 – Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.

As of September 30, 2018, the carrying value of cash and cash equivalents, short-term investments, accounts receivable, accounts payable, and the contingent consideration liability included in accrued expenses approximated their fair value due to the nature of these financial instruments. The Company invests in money market funds, commercial paper, time deposits and debt securities that are classified as cash and cash equivalents within the accompanying condensed consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. These investments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company’s short-term investments of $105 million at September 30, 2018 consist of certificates of deposit with initial maturities of greater than three months when purchased that mature within one year from the balance sheet date. These investments, which are classified within Level 1 of the fair value hierarchy, are carried at fair value, which approximated historical cost at September 30, 2018. The carrying amount and estimated fair value of the Company’s total long-term debt was $62.9 billion and $62.8 billion, respectively, as of September 30, 2018. The fair value of the Company’s long-term debt was estimated based on quoted prices currently offered in active markets for the Company’s debt, which is considered Level 1 of the fair value hierarchy.

Accounts Receivable, Net

Included within accounts receivable, net are the following, which are reflected net of allowance for doubtful accounts, customer credit allowances, and contractual allowances:

|  | September 30, |  | December 31,
In millions |  | 2018 |  | 2017
Trade receivables |  | $ | 7,258 |  | $ | 7,873
Vendor and manufacturer receivables |  |  | 6,991 |  |  | 5,109
Other receivables |  |  | 588 |  |  | 199
Total accounts receivable, net |  | $ | 14,837 |  | $ | 13,181

Related Party Transactions

The Company has an equity method investment in SureScripts, LLC (“SureScripts”), which operates a clinical health information network. The PSS and RLS utilize this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of approximately $4 million and $5 million in the three months ended September 30, 2018 and 2017, respectively, and expensed fees for the use of this network of approximately $34 million and $29 million in the nine months ended September 30, 2018 and 2017, respectively. The Company’s investment in and equity in earnings of SureScripts for all periods presented is immaterial.

9

Table of Contents

The Company has an equity method investment in Heartland Healthcare Services (“Heartland”). Heartland operates several long-term care pharmacies in four states. Heartland paid the Company approximately $34 million and $36 million for pharmaceutical inventory purchases during the three months ended September 30, 2018 and 2017, respectively, and $105 million and $106 million for pharmaceutical inventory purchases during the nine months ended September 30, 2018 and 2017, respectively. Additionally, the Company performs certain collection functions for Heartland and then passes those customer cash collections back to Heartland. The Company’s investment in and equity in earnings of Heartland for all periods presented is immaterial.

Discontinued Operations

In connection with certain business dispositions completed between 1991 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Bob’s Stores and Linens ‘n Things, both of which subsequently filed for bankruptcy. See “Note 11 – Commitments and Contingencies” to the condensed consolidated financial statements. The Company’s discontinued operations include lease-related costs which the Company believes it will likely be required to satisfy pursuant to its lease guarantees.

Adoption of New Revenue Recognition Standard

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08, Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net) which amends the principal-versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, Identifying Performance Obligations and Licensing, which amends the guidance in those areas in the new revenue recognition standard.

The Company adopted the new revenue recognition standard as of January 1, 2018 using the modified retrospective method and applying the new standard to all contracts. Therefore, the comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods. One difference was identified between the previous accounting guidance and the new accounting guidance in the RLS related to the accounting for the Company’s ExtraBucks® Rewards customer loyalty program, which was previously accounted for under a cost deferral method. Under the new standard, this program is accounted for under a revenue deferral method. The Company recognized the cumulative effect of initially applying the new revenue recognition standard as an adjustment to beginning retained earnings. On January 1, 2018, the Company recorded an after-tax transition adjustment to reduce retained earnings by approximately $13 million ($17 million prior to tax effect). The Company expects the impact of the adoption of the new standard to be immaterial to its net revenue and net income on an ongoing basis.

The following is a discussion of the Company’s revenue recognition policies by segment under the new revenue recognition accounting standard:

Pharmacy Services Segment

The PSS sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through its retail pharmacy network. The Company’s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. Pharmacy benefit management services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.

The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related pharmacy benefit management services.

10

Table of Contents

Net revenues include (i) the portion of the price the client pays directly to the PSS, net of any discounts earned on brand drugs or other discounts and refunds paid back to the client (see “Drug Discounts” and “Guarantees” below), (ii) the price paid to the PSS by client plan members for mail order prescriptions (“Mail Co-Payments”) and the price paid to retail network pharmacies by client plan members for retail prescriptions (“Retail Co-Payments”), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenue.

The PSS recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those prescription drugs. The following revenue recognition policies have been established for the PSS:

| · |  | Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the PSS has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.

| · |  | Revenues generated from prescription drugs sold by third party pharmacies in the PSS’ retail pharmacy network and associated administrative fees are recognized at the PSS’ point-of-sale, which is when the claim is adjudicated by the PSS’ online claims processing system and the Company has transferred control of the prescription drug and performed all of its performance obligations.

For contracts under which the PSS acts as an agent or does not control the prescription drugs prior to transfer to the client, revenue is recognized using the net method.

Drug discounts – The PSS records revenue net of manufacturers’ rebates, earned by its clients based on their plan members’ utilization of brand-name formulary drugs. The PSS estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers’ rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The PSS adjusts its rebates payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues as identified. Adjustments generally result from contract changes with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the product was included in the applicable formulary. The effect of adjustments between estimated and actual amounts have not been material to the Company’s results of operations or financial position.

Guarantees – The PSS also adjusts revenues for refunds owed to the client resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual amounts have not been material to the Company’s results of operations or financial position.

Medicare Part D – The PSS participates in the federal government’s Medicare Part D program as a prescription drug plan (“PDP”) through its SilverScript subsidiary. Net revenues include insurance premiums earned by the PDP, which are determined based on the PDP’s annual bid and related contractual arrangements with the United States Centers for Medicare and Medicaid Services (“CMS”). The insurance premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within accrued expenses and other current liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.

In addition to these premiums, net revenues include co-payments, coverage gap benefits, deductibles and co-insurance (collectively, the “Member Co-Payments”) related to PDP members’ actual prescription claims. In certain cases, CMS subsidizes a portion of these Member Co-Payments and the PSS is paid an estimated prospective Member Co-Payment subsidy, each month. If the prospective Member Co-Payment subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable or accrued expenses. The PSS accounts for Member Co-Payments (including the amounts subsidized by CMS) using the gross method consistent with revenue recognition policies for Mail Co-Payments and Retail Co-Payments. The Company estimates variable consideration in the form of amounts payable, or receivable from CMS under a risk-sharing feature of the Medicare Part D program design, referred to as the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received or owed to CMS at the end of the reporting year. The Company also estimates cost of revenues for claims that

11

Table of Contents

have been reported and are in the process of being paid or contested and for its estimate of claims that have been incurred but have not yet been reported. Historically, the effect of these adjustments has not been material to the Company’s results of operations or financial position.

Retail/LTC Segment

Retail Pharmacy - The retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to the third party payer for pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual amounts have not been material to the Company’s results of operations or financial position.

Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.

Customer returns are not material to the Company’s results of operations or financial position.

Loyalty Program - The Company’s customer loyalty program, ExtraCare®, is comprised of two components, ExtraSavings TM and ExtraBucks® Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level.

ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed rewards are reflected as a contract liability.

Long-term Care - Revenue is recognized when control of the promised goods or services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of the revenue from sales of pharmaceutical and medical products are reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as other third party insurance payors, and reduces revenue at the revenue recognition date, to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total net revenues and receivables reported in the Company’s financial statements are recorded at the amount expected to be ultimately received from these payors.

Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors are typically not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.

Health Care Clinics - For services provided by the Company’s health care clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.

12

Table of Contents

Disaggregation of Revenue

The following table disaggregates the Company’s revenue by major source in each segment for the three and nine months ended September 30, 2018:

|  | Pharmacy |  |  |  | Intersegment |  | Consolidated
In millions |  | Services |  | Retail/LTC |  | Eliminations |  | Totals
Three Months Ended September 30, 2018 |  |  |  |  |  |  |  |  |  |  |  |
Major goods/services lines: |  |  |  |  |  |  |  |  |  |  |  |
Pharmacy |  | $ | 32,995 |  | $ | 16,123 |  | $ | (7,350) |  | $ | 41,768
Front Store |  |  | — |  |  | 4,557 |  |  | — |  |  | 4,557
Other |  |  | 768 |  |  | 176 |  |  | — |  |  | 944
Total |  | $ | 33,763 |  | $ | 20,856 |  | $ | (7,350) |  | $ | 47,269
Pharmacy Services distribution channel: |  |  |  |  |  |  |  |  |  |  |  |
Mail choice (1) |  | $ | 11,812 |  |  |  |  |  |  |  |  |
Pharmacy network (2) |  |  | 21,183 |  |  |  |  |  |  |  |  |
Other |  |  | 768 |  |  |  |  |  |  |  |  |
Total |  | $ | 33,763 |  |  |  |  |  |  |  |  |
Nine Months Ended September 30, 2018 |  |  |  |  |  |  |  |  |  |  |  |
Major goods/services lines: |  |  |  |  |  |  |  |  |  |  |  |
Pharmacy |  | $ | 96,110 |  | $ | 47,428 |  | $ | (21,518) |  | $ | 122,020
Front Store |  |  | — |  |  | 13,990 |  |  | — |  |  | 13,990
Other |  |  | 3,118 |  |  | 542 |  |  | — |  |  | 3,660
Total |  | $ | 99,228 |  | $ | 61,960 |  | $ | (21,518) |  | $ | 139,670
Pharmacy Services distribution channel: |  |  |  |  |  |  |  |  |  |  |  |
Mail choice (1) |  | $ | 34,807 |  |  |  |  |  |  |  |  |
Pharmacy network (2) |  |  | 61,303 |  |  |  |  |  |  |  |  |
Other |  |  | 3,118 |  |  |  |  |  |  |  |  |
Total |  | $ | 99,228 |  |  |  |  |  |  |  |  |

| (1) |  | Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at retail, as well as prescriptions filled at our retail pharmacies under the Maintenance Choice® program.

| (2) |  | Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including our retail pharmacies and long-term care pharmacies, but excluding Maintenance Choice activity, which is included within the mail choice category.

Contract Balances

Contract liabilities primarily represent the Company’s obligation to transfer additional goods or services to a customer for which the Company has received consideration, for example ExtraBucks® Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the retail customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.

The following table provides information about receivables and contract liabilities from contracts with customers:

|  | September 30, |  | December 31,
In millions |  | 2018 |  | 2017
Trade receivables (included in accounts receivable, net) |  | $ | 7,258 |  | $ | 7,873
Contract liabilities (included in accrued expenses) |  |  | 63 |  |  | 53

13

Table of Contents

During the nine months ended September 30, 2018, the contract liabilities balance includes increases related to customers’ earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of the changes:

In millions |  |
Balance, December 31, 2017 |  | $ | 53
Adoption of ASU 2014-09 |  |  | 17
Loyalty program earnings and gift card issuances |  |  | 236
Redemption and breakage |  |  | (243)
Balance, September 30, 2018 |  | $ | 63

Impact of New Revenue Recognition Standard on Financial Statement Line Items

The Company adopted ASU 2014-09 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts was recorded as an adjustment to retained earnings as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue guidance, the following adjustments were made to accounts on the condensed consolidated balance sheet as of January 1, 2018:

|  | Impact of Change in Accounting Policy
|  | As Reported |  |  |  |  | Adjusted
In millions |  | December 31, 2017 |  | Adjustments |  | January 1, 2018
Condensed Consolidated Balance Sheet: |  |  |  |  |  |  |  |  |
Accrued expenses |  | $ | 6,609 |  | $ | 17 |  | $ | 6,626
Deferred income taxes |  |  | 2,996 |  |  | (4) |  |  | 2,992
Total liabilities |  |  | 57,436 |  |  | 13 |  |  | 57,449
Retained earnings |  |  | 43,556 |  |  | (13) |  |  | 43,543
Total CVS Health shareholders' equity |  |  | 37,691 |  |  | (13) |  |  | 37,678
Total shareholders' equity |  |  | 37,695 |  |  | (13) |  |  | 37,682

The following tables compare the reported condensed consolidated balance sheet, statements of operations, and statement of cash flows to the pro forma amounts had the previous revenue accounting guidance remained in effect:

|  | Impact of Change in Accounting Policy
|  | As Reported |  |  |  |  | Balances
|  | For the |  |  |  |  | Without
|  | Three Months Ended |  |  |  |  | Adoption of
In millions |  | September 30, 2018 |  | Adjustments |  | Topic 606
Condensed Consolidated Statement of Operations: |  |  |  |  |  |  |  |  |
Net revenues |  | $ | 47,269 |  | $ | (6) |  | $ | 47,263
Cost of revenues |  |  | 39,941 |  |  | (3) |  |  | 39,938
Gross profit |  |  | 7,328 |  |  | (3) |  |  | 7,325
Operating profit |  |  | 2,353 |  |  | (3) |  |  | 2,350
Income before income tax provision |  |  | 1,899 |  |  | (3) |  |  | 1,896
Income tax provision |  |  | 509 |  |  | (1) |  |  | 508
Income from continuing operations |  |  | 1,390 |  |  | (2) |  |  | 1,388
Net income |  |  | 1,390 |  |  | (2) |  |  | 1,388
Net income attributable to CVS Health |  |  | 1,390 |  |  | (2) |  |  | 1,388

14

Table of Contents

|  | Impact of Change in Accounting Policy
|  | As Reported |  |  |  |  | Balances
|  | As of/For the |  |  |  |  | Without
|  | Nine Months Ended |  |  |  |  | Adoption of
In millions |  | September 30, 2018 |  | Adjustments |  | Topic 606
Condensed Consolidated Statement of Operations: |  |  |  |  |  |  |  |  |
Net revenues |  | $ | 139,670 |  | $ | 4 |  | $ | 139,674
Cost of revenues |  |  | 118,282 |  |  | 3 |  |  | 118,285
Gross profit |  |  | 21,388 |  |  | 1 |  |  | 21,389
Operating profit |  |  | 2,712 |  |  | 1 |  |  | 2,713
Income before income tax provision |  |  | 1,304 |  |  | 1 |  |  | 1,305
Income tax provision |  |  | 1,478 |  |  | — |  |  | 1,478
Loss from continuing operations |  |  | (174) |  |  | 1 |  |  | (173)
Net loss |  |  | (175) |  |  | 1 |  |  | (174)
Net loss attributable to CVS Health |  |  | (175) |  |  | 1 |  |  | (174)
Condensed Consolidated Balance Sheet: |  |  |  |  |  |  |  |  |
Accrued expenses |  |  | 6,160 |  |  | (18) |  |  | 6,142
Deferred income taxes |  |  | 3,052 |  |  | 4 |  |  | 3,056
Total liabilities |  |  | 94,884 |  |  | (14) |  |  | 94,870
Retained earnings |  |  | 41,843 |  |  | 14 |  |  | 41,857
Total CVS Health shareholders' equity |  |  | 36,618 |  |  | 14 |  |  | 36,632
Total shareholders' equity |  |  | 36,622 |  |  | 14 |  |  | 36,636
Condensed Consolidated Statement of Cash Flow: |  |  |  |  |  |  |  |  |
Reconciliation of net loss to net cash provided by operating activities: |  |  |  |  |  |  |  |  |
Net loss |  |  | (175) |  |  | 1 |  |  | (174)
Accrued expenses |  |  | (341) |  |  | (1) |  |  | (342)

Other Accounting Pronouncements Recently Adopted

In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This ASU requires equity investments, except those under the equity method of accounting or those that result in the consolidation of an investee, to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. This simplifies the impairment assessment of equity investments previously held at cost. Entities are required to apply the guidance retrospectively, with the exception of the amendments related to equity investments without readily determinable fair values, which must be applied on a prospective basis. Effective January 1, 2018, the Company adopted this new accounting guidance. The adoption of this new guidance did not have a material impact on the Company’s financial position or results of operations.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 is intended to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows and to eliminate the diversity in practice related to such classifications. Effective January 1, 2018, the Company adopted this new accounting guidance. The adoption of this new guidance did not have a material impact on the Company’s financial position or results of operations.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows, which amends Accounting Standard Codification (“ASC”) Topic 230. This ASU requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities are no longer required to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. When cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows

15

Table of Contents

to the related captions in the balance sheet. Entities will also have to disclose the nature of their restricted cash and restricted cash equivalent balances. The guidance is required to be applied retrospectively. Effective January 1, 2018, the Company adopted this new accounting guidance. The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheet to total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows:

|  | September 30, |  | December 31,
In millions |  | 2018 |  | 2017
Cash and cash equivalents |  | $ | 41,587 |  | $ | 1,696
Restricted cash (included in other current assets) |  |  | 11 |  |  | 14
Restricted cash (included in other assets) |  |  | 229 |  |  | 190
Total cash, cash equivalents and restricted cash in the statement of cash flows |  | $ | 41,827 |  | $ | 1,900

Restricted cash included in other current assets in the condensed consolidated balance sheets represents amounts held in escrow accounts in connection with certain recent acquisitions. Restricted cash included in other assets in the condensed consolidated balance sheets represents amounts held in a trust in the Company’s insurance captive to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits, money markets, and commercial paper, which are classified within Level 1 of the fair value hierarchy.

Restricted cash activity was previously reported in “acquisitions (net of cash acquired) and other investments” within investing cash flows on the Company’s condensed consolidated statement of cash flows. The following is a reconciliation of the effect on the relevant line items on the statement of cash flows for the nine months ended September 30, 2017 as a result of adopting this new accounting guidance:

|  | As Previously |  |  |  |  |  |
In millions |  | Reported |  | Adjustments |  | As Revised
Nine Months Ended September 30, 2017 |  |  |  |  |  |  |  |  |
Acquisitions (net of cash acquired) and other investments |  | $ | (502) |  | $ | 41 |  | $ | (461)
Net cash used in investing activities |  |  | (1,608) |  |  | 41 |  |  | (1,567)
Net decrease in cash, cash equivalents and restricted cash (1) |  |  | (886) |  |  | 41 |  |  | (845)
Cash, cash equivalents, and restricted cash at the beginning of the period (1) |  |  | 3,371 |  |  | 149 |  |  | 3,520
Cash, cash equivalents, and restricted cash at the end of the period (1) |  |  | 2,485 |  |  | 190 |  |  | 2,675

| (1) |  | Prior to the adoption of ASU 2016-18, these financial statement captions excluded restricted cash. The financial statement captions have been renamed to reflect the inclusion of restricted cash subsequent to the adoption of ASU 2016-18 on January 1, 2018.

In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (“ASU 2018-02”). ASU 2018-02 permits entities to reclassify tax effects stranded in accumulated other comprehensive income as a result of the Tax Cuts and Jobs Act (“TCJA”) to retained earnings. The guidance states that because the adjustment of deferred income taxes due to the reduction of the historical corporate income tax rate to the newly enacted corporate income tax rate was required to be included in income from continuing operations, the tax effects of items within accumulated other comprehensive income (“stranded tax effects”) are not reflected at the appropriate tax rate. During the first quarter of 2018, the Company elected to early adopt this new standard and decreased accumulated other comprehensive income and increased retained earnings in the period of adoption by $7 million due to the change in the U.S. federal corporate income tax rate in December 2017. See “Note 6 – Accumulated Other Comprehensive Income (Loss)” to the condensed consolidated financial statements for the impact of the adoption of this standard on accumulated other comprehensive income for the nine months ended September 30, 2018.

New Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model

16

Table of Contents

(e.g., certain definitions, such as initial direct costs, have been updated) and the new revenue recognition standard. The Company will adopt this new standard on January 1, 2019. The Company intends to adopt the standard on a modified retrospective basis. The Company has a cross-functional project team focused on the implementation of the new accounting standard. The project involves among other things the implementation of new leasing systems capable of producing the data to prepare the required accounting and disclosures under the new accounting standard. The Company expects to complete this project during the fourth quarter of 2018. Although management continues to evaluate the effect on the Company’s consolidated financial statements and disclosures, management currently estimates total assets and liabilities will increase approximately $19 billion to $21 billion upon adoption. This estimate may change as the Company’s implementation progresses, the Company’s lease portfolio changes, and discount rates fluctuate prior to the date of adoption. Management does not expect the new standard will have a material impact on the Company’s consolidated results of operations or cash flows.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326). The new standard requires the use of a forward-looking expected loss impairment model for trade and other receivables, held-to-maturity debt securities, loans and other instruments. The new standard also requires impairments and recoveries for available-for-sale debt securities to be recorded through an allowance account and revises certain disclosure requirements. The Company is currently evaluating the effect that implementation of this standard will have on the Company’s consolidated results of operations, cash flows, financial position and related disclosures.

In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and other – Internal-Use Software (Topic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. The new standard requires a customer in a cloud computing arrangement that is a service contract to follow internal-use software guidance in Topic 350-40 to determine which implementation costs to capitalize as assets. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the effect the implementation of this standard will have on the Company’s consolidated results of operations, cash flows, financial position and related disclosures.

Note 2 – Proposed Acquisition of Aetna

On December 3, 2017, the Company entered into a definitive merger agreement to acquire all of the outstanding shares of Aetna Inc. (“Aetna”) for a combination of cash and stock. Under the terms of the merger agreement, Aetna shareholders will receive $145.00 per share in cash and 0.8378 CVS Health shares for each Aetna share. The transaction values Aetna at approximately $207 per share or approximately $69 billion based on the Company’s 5-day volume weighted average price ending December 1, 2017 of $74.21 per share. Including the assumption of Aetna’s debt, the total value of the transaction is approximately $77 billion. The final purchase price will be determined based on the Company’s stock price on the date of closing of the transaction.

The proposed transaction was approved by stockholders of CVS Health and shareholders of Aetna at meetings held on March 13, 2018. On October 10, 2018, the Company and Aetna entered into a consent decree with the United States Department of Justice (“DOJ”) that allows the Company’s proposed acquisition of Aetna to proceed, provided Aetna agreed to sell its individual standalone Medicare Part D prescription drug plans. As part of the agreement reached with the DOJ, Aetna entered into an asset purchase agreement with a subsidiary of WellCare Health Plans, Inc. for the divestiture of Aetna’s standalone Medicare Part D prescription drug plans, which have an aggregate of approximately 2.2 million members. Closing of the divestiture is subject to the closing of the Company’s proposed acquisition of Aetna. The required asset preservation stipulation and order was entered by the U.S. District Court for the District of Columbia on October 25, 2018. There are no remaining antitrust impediments to closing the proposed acquisition of Aetna. The proposed acquisition of Aetna remains subject to customary closing conditions, including the approvals of state departments of insurance.

If the transaction is not completed, the Company could be liable to Aetna for a termination fee of $2.1 billion in connection with the merger agreement, depending on the reasons leading to such termination.

17

Table of Contents

Note 3 – Goodwill and Intangible Assets

Goodwill is not amortized, but is subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate there may be impairment. Goodwill is evaluated for possible impairment by comparing the fair value of a reporting unit to its carrying value, including the goodwill assigned to that reporting unit.

During 2018, the LTC reporting unit has continued to experience challenges that have impacted management’s ability to grow the business at the rate that was originally estimated when the Company made the acquisition of Omnicare, Inc. and when the prior year annual goodwill impairment test was performed. These challenges include lower client retention rates, lower occupancy rates in skilled nursing facilities, the deteriorating financial health of numerous skilled nursing facility customers, and continued facility reimbursement pressures. In June 2018, LTC management submitted their initial budget for 2019 and updated their 2018 annual forecast which showed a deterioration in the financial results for the remainder of 2018 and in 2019, which also caused management to update their long term forecast beyond 2019. Based on these updated projections, management determined that there were indicators that the LTC reporting unit’s goodwill may be impaired and, accordingly, an interim goodwill impairment test was performed during the second quarter of 2018. The results of the impairment test showed that the fair value of the LTC reporting unit was lower than the carrying value, resulting in a $3.9 billion pre-tax goodwill impairment charge in the second quarter of 2018. The fair value of the LTC reporting unit was determined using a combination of a discounted cash flow method and a market multiple method. In addition to the lower financial projections, higher risk-free interest rates and lower market multiples of the peer group companies contributed to the amount of the goodwill impairment charge. As of September 30, 2018, the remaining goodwill balance in the LTC reporting unit is approximately $2.7 billion.

During the third quarter of 2018, the Company performed its required annual impairment tests and concluded there was no impairment of goodwill or trade names.

On January 2, 2018, the Company sold RxCrossroads (“RxC”) to McKesson Corporation for $725 million, at which time the remaining goodwill of this reporting unit was removed from the condensed consolidated balance sheet.

Below is a summary of the changes in the carrying value of goodwill by segment for the nine months ended September 30, 2018:

|  | Pharmacy |  |  |  |  |  |
In millions |  | Services |  | Retail/LTC |  | Total
Balance, December 31, 2017 |  | $ | 21,819 |  | $ | 16,632 |  | $ | 38,451
Acquisitions |  |  | 67 |  |  | 35 |  |  | 102
Foreign currency translation adjustments |  |  | — |  |  | (18) |  |  | (18)
Divestiture of RxCrossroads subsidiary |  |  | — |  |  | (398) |  |  | (398)
Impairment |  |  | — |  |  | (3,921) |  |  | (3,921)
Balance, September 30, 2018 |  | $ | 21,886 |  | $ | 12,330 |  | $ | 34,216

The following is a summary of the Company’s intangible assets as of September 30, 2018 and December 31, 2017:

|  | September 30, 2018 |  | December 31, 2017
|  | Gross |  |  |  |  | Net |  | Gross |  |  |  |  | Net
|  | Carrying |  | Accumulated |  | Carrying |  | Carrying |  | Accumulated |  | Carrying
In millions |  | Amount |  | Amortization |  | Amount |  | Amount |  | Amortization |  | Amount
Trademark (indefinitely-lived) |  | $ | 6,398 |  | $ | — |  | $ | 6,398 |  | $ | 6,398 |  | $ | — |  | $ | 6,398
Customer contracts and relationships and covenants not to compete |  |  | 12,507 |  |  | (6,059) |  |  | 6,448 |  |  | 12,341 |  |  | (5,536) |  |  | 6,805
Favorable leases and other |  |  | 1,125 |  |  | (805) |  |  | 320 |  |  | 1,190 |  |  | (763) |  |  | 427
|  | $ | 20,030 |  | $ | (6,864) |  | $ | 13,166 |  | $ | 19,929 |  | $ | (6,299) |  | $ | 13,630

18

Table of Contents

Note 4 – Borrowings and Credit Agreements

|  | September 30, |  | December 31,
In millions |  | 2018 |  | 2017
Short-term debt |  |  |  |  |  |
Commercial paper |  | $ | — |  | $ | 1,276
Long-term debt |  |  |  |  |  |
3.25% senior exchange debentures due 2035 |  |  | — |  |  | 1
1.9% senior notes due 2018 |  |  | — |  |  | 2,250
2.25% senior notes due 2018 |  |  | 1,250 |  |  | 1,250
2.25% senior notes due 2019 |  |  | 850 |  |  | 850
2.8% senior notes due 2020 |  |  | 2,750 |  |  | 2,750
3.125% senior notes due 2020 |  |  | 2,000 |  |  | —
Floating rate notes due 2020 |  |  | 1,000 |  |  | —
2.125% senior notes due 2021 |  |  | 1,750 |  |  | 1,750
4.125% senior notes due 2021 |  |  | 550 |  |  | 550
3.35% senior notes due 2021 |  |  | 3,000 |  |  | —
Floating rate notes due 2021 |  |  | 1,000 |  |  | —
2.75% senior notes due 2022 |  |  | 1,250 |  |  | 1,250
3.5% senior notes due 2022 |  |  | 1,500 |  |  | 1,500
4.75% senior notes due 2022 |  |  | 399 |  |  | 399
4% senior notes due 2023 |  |  | 1,250 |  |  | 1,250
3.7% senior notes due 2023 |  |  | 6,000 |  |  | —
3.375% senior notes due 2024 |  |  | 650 |  |  | 650
5% senior notes due 2024 |  |  | 299 |  |  | 299
3.875% senior notes due 2025 |  |  | 2,828 |  |  | 2,828
4.1% senior notes due 2025 |  |  | 5,000 |  |  | —
2.875% senior notes due 2026 |  |  | 1,750 |  |  | 1,750
6.25% senior notes due 2027 |  |  | 372 |  |  | 372
4.3% senior notes due 2028 |  |  | 9,000 |  |  | —
4.875% senior notes due 2035 |  |  | 652 |  |  | 652
4.78% senior notes due 2038 |  |  | 5,000 |  |  | —
6.125% senior notes due 2039 |  |  | 447 |  |  | 447
5.75% senior notes due 2041 |  |  | 133 |  |  | 133
5.3% senior notes due 2043 |  |  | 750 |  |  | 750
5.125% senior notes due 2045 |  |  | 3,500 |  |  | 3,500
5.05% senior notes due 2048 |  |  | 8,000 |  |  | —
Capital lease obligations |  |  | 672 |  |  | 670
Other |  |  | 18 |  |  | 43
Total debt principal |  |  | 63,620 |  |  | 27,170
Debt premiums |  |  | 25 |  |  | 28
Debt discounts and deferred financing costs |  |  | (759) |  |  | (196)
|  |  | 62,886 |  |  | 27,002
Less: |  |  |  |  |  |
Short-term debt (commercial paper) |  |  | — |  |  | (1,276)
Current portion of long-term debt |  |  | (2,139) |  |  | (3,545)
Long-term debt |  | $ | 60,747 |  | $ | 22,181

The Company did not have any commercial paper outstanding as of September 30, 2018. In connection with its commercial paper program, the Company maintains a $1.75 billion 364-day unsecured back-up credit facility, which expires on May 16, 2019, a $1.25 billion, five-year unsecured back-up credit facility, which expires on July 1, 2020, a $1.0 billion, five-year unsecured back-up credit facility, which expires on May 18, 2022, and a $2.0 billion, five-year unsecured back-up credit facility, which expires on May 17, 2023. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company’s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of September 30, 2018 and December 31, 2017, there were no borrowings outstanding under the back-up credit facilities.

19

Table of Contents

On March 9, 2018, the Company issued an aggregate of $40.0 billion of floating rate notes and unsecured senior notes, collectively the “Notes”, for total proceeds of approximately $39.4 billion, net of discounts and underwriting fees, comprised of the following:

In millions |  |  |
3.125% senior notes due 2020 |  | $ | 2,000
Floating rate notes due 2020 |  |  | 1,000
3.35% senior notes due 2021 |  |  | 3,000
Floating rate notes due 2021 |  |  | 1,000
3.7% senior notes due 2023 |  |  | 6,000
4.1% senior notes due 2025 |  |  | 5,000
4.3% senior notes due 2028 |  |  | 9,000
4.78% senior notes due 2038 |  |  | 5,000
5.05% senior notes due 2048 |  |  | 8,000
Total debt principal |  | $ | 40,000

The Notes pay interest semi-annually and contain redemption terms which allow or require the Company to redeem the Notes at a defined redemption price plus accrued and unpaid interest at the redemption date. The net proceeds of the Notes will be used to fund the proposed acquisition of Aetna.

If the proposed acquisition of Aetna has not been completed by September 3, 2019 (the “Outside Date”) or if, prior to such date, the merger agreement is terminated or the Company otherwise publicly announces that the merger will not be consummated, then the Company will be required to redeem all outstanding 2020 Floating Rate Notes, 2021 Floating Rate Notes, 2020 Notes, 2021 Notes, 2023 Notes, 2025 Notes, 2028 Notes and 2038 Notes at a redemption price equal to 101% of the aggregate principal amount of those notes plus accrued and unpaid interest. The 2048 Notes are not subject to this mandatory redemption provision.

On December 3, 2017, in connection with the proposed acquisition of Aetna, the Company entered into a $49.0 billion unsecured bridge loan facility commitment. The Company paid approximately $221 million in fees upon entering into the agreement. The fees were capitalized in other current assets and are being amortized as interest expense over the period the bridge loan facility commitment is outstanding. The bridge loan facility commitment was reduced to $44.0 billion on December 15, 2017 upon the Company entering into a $5.0 billion term loan agreement. As discussed above, on March 9, 2018, the Company issued unsecured senior notes with an aggregate principal of $40.0 billion. At this time, the bridge loan facility commitment was reduced to $4.0 billion and the Company paid approximately $8 million in fees to retain the bridge loan facility commitment through the date of the proposed acquisition of Aetna. These fees were capitalized in other current assets and are being amortized as interest expense over the period the bridge loan facility commitment is outstanding. The Company recorded $2 million and $171 million of amortization of the bridge loan facility commitment fees during the three and nine months ended September 30, 2018, respectively, which was recorded in “Interest expense, net” on the condensed consolidated statements of operations. On October 26, 2018, the Company entered into a $4.0 billion unsecured 364-day bridge term loan agreement to formalize the bridge loan facility discussed above.

The back-up credit facilities, unsecured senior notes, and term loan agreement contain customary restrictive financial and operating covenants. These covenants do not include a requirement for the acceleration of the Company’s debt maturities in the event of a downgrade in the Company’s credit rating. The Company does not believe the restrictions contained in these covenants materially affect its financial or operating flexibility. As of September 30, 2018, the Company is in compliance with all debt covenants.

Note 5 – Share Repurchase Programs

The following share repurchase programs have been authorized by the Company’s Board of Directors:

In billions |  |  |  |  |
|  |  |  |  | Remaining as of
Authorization Date |  | Authorized |  | September 30, 2018
November 2, 2016 (“2016 Repurchase Program”) |  | $ | 15.0 |  | $ | 13.9
December 15, 2014 (“2014 Repurchase Program”) |  |  | 10.0 |  |  | —

20

Table of Contents

The share Repurchase Programs, each of which was effective immediately, permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (“ASR”) transactions, and/or other derivative transactions. The 2014 Repurchase Program was completed during the second quarter of 2017. The 2016 Repurchase Program can be modified or terminated by the Board of Directors at any time.

During the nine months ended September 30, 2018, the Company did not repurchase any shares of common stock pursuant to the 2016 Repurchase Program.

Pursuant to the authorization under the 2014 Repurchase Program, effective August 29, 2016, the Company entered into two fixed dollar ASRs with Barclays Bank PLC (“Barclays”) for a total of $3.6 billion. Upon payment of the $3.6 billion purchase price on January 6, 2017, the Company received a number of shares of its common stock equal to 80% of the $3.6 billion notional amount of the ASRs or approximately 36.1 million shares, which were placed into treasury stock in January 2017. The ASRs were accounted for as an initial treasury stock transaction for $2.9 billion and a forward contract for $0.7 billion. In April 2017, the Company received 9.9 million shares of common stock, representing the remaining 20% of the $3.6 billion notional amount of the ASRs, thereby concluding the ASRs. The remaining 9.9 million shares of common stock delivered to the Company by Barclays were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in April 2017.

At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share.

Note 6 – Accumulated Other Comprehensive Income (Loss)

Accumulated other comprehensive income (loss) consists of foreign currency translation adjustments, cash flow hedges associated with the forecasted issuance of long-term debt, and changes in the net actuarial gains and losses associated with pension and other postretirement benefit plans. The following table summarizes the activity within the components of accumulated other comprehensive income.

Changes in accumulated other comprehensive income (loss) by component is shown on the following tables:

|  | Three Months Ended September 30, 2018 (1)
|  |  |  |  |  |  | Pension and |  |  |
|  |  |  |  |  |  | Other |  |  |
|  | Foreign |  | Cash Flow |  | Postretirement |  |  |
In millions |  | Currency |  | Hedges |  | Benefits |  | Total
Balance, June 30, 2018 |  | $ | (155) |  | $ | 321 |  | $ | (25) |  | $ | 141
Other comprehensive loss: |  |  |  |  |  |  |  |  |  |  |  |
Other comprehensive loss before reclassifications |  |  | (8) |  |  | — |  |  | — |  |  | (8)
Amounts reclassified from accumulated other comprehensive income (2) |  |  | — |  |  | (4) |  |  | — |  |  | (4)
Other comprehensive loss |  |  | (8) |  |  | (4) |  |  | — |  |  | (12)
Balance, September 30, 2018 |  | $ | (163) |  | $ | 317 |  | $ | (25) |  | $ | 129

|  | Three Months Ended September 30, 2017 (1)
|  |  |  |  |  |  |  | Pension and |  |  |
|  |  |  |  |  |  | Other |  |  |
|  | Foreign |  | Cash Flow |  | Postretirement |  |  |
|  | Currency |  | Hedges |  | Benefits |  | Total
Balance, June 30, 2017 |  | $ | (129) |  | $ | (4) |  | $ | (173) |  | $ | (306)
Other comprehensive income: |  |  |  |  |  |  |  |  |  |  |  |
Other comprehensive income before reclassifications |  |  | 8 |  |  | — |  |  | — |  |  | 8
Amounts reclassified from accumulated other comprehensive income (loss) (2) |  |  | — |  |  | — |  |  | 151 |  |  | 151
Other comprehensive income |  |  | 8 |  |  | — |  |  | 151 |  |  | 159
Balance, September 30, 2017 |  | $ | (121) |  | $ | (4) |  | $ | (22) |  | $ | (147)

21

Table of Contents

|  | Nine Months Ended September 30, 2018 (1)
|  |  |  |  |  |  | Pension and |  |  |
|  |  |  |  |  |  | Other |  |  |
|  | Foreign |  | Cash Flow |  | Postretirement |  |  |
|  | Currency |  | Hedges |  | Benefits |  | Total
Balance, December 31, 2017 |  | $ | (129) |  | $ | (15) |  | $ | (21) |  | $ | (165)
Reclassifications to retained earnings in accordance with ASU 2018-02 (3) |  |  | — |  |  | (3) |  |  | (4) |  |  | (7)
|  |  | (129) |  |  | (18) |  |  | (25) |  |  | (172)
Other comprehensive income (loss): |  |  |  |  |  |  |  |  |  |  |  |
Other comprehensive income (loss) before reclassifications |  |  | (34) |  |  | 344 |  |  | — |  |  | 310
Amounts reclassified from accumulated other comprehensive income (loss) (2) |  |  | — |  |  | (9) |  |  | — |  |  | (9)
Other comprehensive income (loss) |  |  | (34) |  |  | 335 |  |  | — |  |  | 301
Balance, September 30, 2018 |  | $ | (163) |  | $ | 317 |  | $ | (25) |  | $ | 129

|  | Nine Months Ended September 30, 2017 (1)
|  |  |  |  |  |  |  | Pension and |  |  |
|  |  |  |  |  |  | Other |  |  |
|  | Foreign |  | Cash Flow |  | Postretirement |  |  |
|  | Currency |  | Hedges |  | Benefits |  | Total
Balance, December 31, 2016 |  | $ | (127) |  | $ | (5) |  | $ | (173) |  | $ | (305)
Other comprehensive income: |  |  |  |  |  |  |  |  |  |  |  |
Other comprehensive income before reclassifications |  |  | 6 |  |  | — |  |  | — |  |  | 6
Amounts reclassified from accumulated other comprehensive income (loss) (2) |  |  | — |  |  | 1 |  |  | 151 |  |  | 152
Other comprehensive income |  |  | 6 |  |  | 1 |  |  | 151 |  |  | 158
Balance, September 30, 2017 |  | $ | (121) |  | $ | (4) |  | $ | (22) |  | $ | (147)

| (1) |  | All amounts are net of tax.

| (2) |  | The amounts reclassified from accumulated other comprehensive income for cash flow hedges are recorded within interest expense, net on the condensed consolidated statements of operations. The amounts reclassified from accumulated other comprehensive income for pension and other postretirement benefits are included in other expense on the condensed consolidated statements of operations.

| (3) |  | See “Note 1 – Accounting Policies” to the condensed consolidated financial statements for additional information on the adoption of ASU 2018-02 during the first quarter of 2018.

Beginning in December 2017 and during the first quarter of 2018, the Company entered into several interest rate swap and treasury lock transactions to manage interest rate risk. These agreements were designated as cash flow hedges and were used to hedge the exposure to variability in future cash flows resulting from changes in interest rates related to the anticipated issuance of long-term debt in connection with the proposed acquisition of Aetna.

On March 9, 2018, the Company issued unsecured senior notes with an aggregate principal of $40.0 billion as discussed in “Note 4 – Borrowings and Credit Agreements” to the condensed consolidated financial statements. In connection with the issuance of the Notes, the Company terminated all outstanding cash flow hedges. In connection with the hedge transactions, the Company received a net amount of $446 million from the hedge counterparties upon termination, which was recorded as a deferred gain, net of tax, of $331 million in accumulated other comprehensive income (loss) and will be reclassified as a reduction of interest expense over the life of the underlying debt. The Company expects to reclassify approximately $18 million in gains associated with these cash flow hedges into earnings within the next 12 months.

Note 7 – Stock-Based Compensation

A summary of stock-based compensation for each of the respective periods is as follows:

|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
In millions |  | 2018 |  | 2017 |  | 2018 |  | 2017
Stock-based compensation: |  |  |  |  |  |  |  |  |  |  |  |
Stock options |  | $ | 14 |  | $ | 15 |  | $ | 39 |  | $ | 49
Restricted stock units and performance share units |  |  | 48 |  |  | 50 |  |  | 133 |  |  | 124
Total stock-based compensation |  | $ | 62 |  | $ | 65 |  | $ | 172 |  | $ | 173

22

Table of Contents

Note 8 – Interest Expense, Net

The following are the components of interest expense, net:

|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
In millions |  | 2018 |  | 2017 |  | 2018 |  | 2017
Interest expense |  | $ | 674 |  | $ | 250 |  | $ | 1,886 |  | $ | 759
Interest income |  |  | (221) |  |  | (5) |  |  | (485) |  |  | (15)
Interest expense, net |  | $ | 453 |  | $ | 245 |  | $ | 1,401 |  | $ | 744

Note 9 – Earnings (Loss) Per Share

Earnings (loss) per share is computed using the two-class method. For periods in which the Company reports net income, diluted earnings per share is determined by using the weighted average number of common and dilutive common equivalent shares outstanding during the period, unless the effect is antidilutive. Due to the loss from continuing operations attributable to CVS Health in the nine months ended September 30, 2018, 2 million of potentially dilutive common equivalent shares were excluded from the calculation of diluted earnings per share, as the impact of these shares was antidilutive. In addition, options to purchase 12.3 million and 13.6 million shares of common stock were outstanding, but were not included in the calculation of diluted earnings per share, for the three and nine months ended September 30, 2018, respectively, because the exercise prices of the options were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. For the same reason, options to purchase 10.9 million and 9.9 million shares of common stock were outstanding, but were not included in the calculation of diluted earnings per share, for the three and nine months ended September 30, 2017, respectively.

The following is a reconciliation of basic and diluted earnings (loss) per share from continuing operations for the respective periods:

|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
In millions, except per share amounts |  | 2018 |  | 2017 |  | 2018 |  | 2017
Numerator for earnings (loss) per share calculation: |  |  |  |  |  |  |  |  |  |  |  |
Income (loss) from continuing operations |  | $ | 1,390 |  | $ | 1,285 |  | $ | (174) |  | $ | 3,344
Income from continuing operations allocated to participating securities |  |  | (1) |  |  | (3) |  |  | (3) |  |  | (12)
Income from continuing operations attributable to noncontrolling interests |  |  | — |  |  | — |  |  | — |  |  | (1)
Income (loss) from continuing operations attributable to CVS Health |  | $ | 1,389 |  | $ | 1,282 |  | $ | (177) |  | $ | 3,331
Denominator for earnings (loss) per share calculation: |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares, basic |  |  | 1,020 |  |  | 1,016 |  |  | 1,018 |  |  | 1,022
Effect of dilutive securities |  |  | 2 |  |  | 4 |  |  | — |  |  | 4
Weighted average shares, diluted |  |  | 1,022 |  |  | 1,020 |  |  | 1,018 |  |  | 1,026
Earnings (loss) per share from continuing operations: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 1.36 |  | $ | 1.26 |  | $ | (0.17) |  | $ | 3.26
Diluted |  | $ | 1.36 |  | $ | 1.26 |  | $ | (0.17) |  | $ | 3.25

23

Table of Contents

Note 10 – Segment Reporting

The Company has two operating segments, Pharmacy Services and Retail/LTC, as well as a Corporate segment.

In conjunction with the Company’s implementation of a new enterprise resource planning system in the first quarter of 2018, the Company changed the manner in which certain shared functional costs are allocated to its reportable segments. Segment financial information for the three and nine months ended September 30, 2017, has been retrospectively adjusted to reflect this change to the cost allocation methodology as shown below:

|  | Three Months Ended September 30, 2017
|  | Pharmacy |  |  |  |  |  |  |  | Intersegment |  | Consolidated
In millions |  | Services |  | Retail/LTC |  | Corporate |  | Eliminations |  | Totals
Cost of revenues, as previously reported |  | $ | 31,251 |  | $ | 13,908 |  |  |  |  | $ | (6,104) |  | $ | 39,055
Adjustments |  |  | 13 |  |  | (4) |  |  |  |  |  | — |  |  | 9
Cost of revenues, as adjusted |  | $ | 31,264 |  | $ | 13,904 |  |  |  |  | $ | (6,104) |  | $ | 39,064
Gross profit, as previously reported |  | $ | 1,645 |  | $ | 5,685 |  |  |  |  | $ | (204) |  | $ | 7,126
Adjustments |  |  | (13) |  |  | 4 |  |  |  |  |  | — |  |  | (9)
Gross profit, as adjusted |  | $ | 1,632 |  | $ | 5,689 |  |  |  |  | $ | (204) |  | $ | 7,117
Operating expenses, as previously reported |  | $ | 292 |  | $ | 4,132 |  | $ | 220 |  | $ | (17) |  | $ | 4,627
Adjustments |  |  | 13 |  |  | (24) |  |  | 2 |  |  | — |  |  | (9)
Operating expenses, as adjusted |  | $ | 305 |  | $ | 4,108 |  | $ | 222 |  | $ | (17) |  | $ | 4,618
Operating profit (loss), as previously reported |  | $ | 1,353 |  | $ | 1,553 |  | $ | (220) |  | $ | (187) |  | $ | 2,499
Adjustments |  |  | (26) |  |  | 28 |  |  | (2) |  |  | — |  |  | —
Operating profit (loss), as adjusted |  | $ | 1,327 |  | $ | 1,581 |  | $ | (222) |  | $ | (187) |  | $ | 2,499

|  | Nine Months Ended September 30, 2017
|  | Pharmacy |  |  |  |  |  |  |  | Intersegment |  | Consolidated
In millions |  | Services |  | Retail/LTC |  | Corporate |  | Eliminations |  | Totals
Cost of revenues, as previously reported |  | $ | 92,234 |  | $ | 41,452 |  |  |  |  | $ | (17,947) |  | $ | 115,739
Adjustments |  |  | 39 |  |  | (12) |  |  |  |  |  | — |  |  | 27
Cost of revenues, as adjusted |  | $ | 92,273 |  | $ | 41,440 |  |  |  |  | $ | (17,947) |  | $ | 115,766
Gross profit, as previously reported |  | $ | 4,210 |  | $ | 17,036 |  |  |  |  | $ | (605) |  | $ | 20,641
Adjustments |  |  | (39) |  |  | 12 |  |  |  |  |  | — |  |  | (27)
Gross profit, as adjusted |  | $ | 4,171 |  | $ | 17,048 |  |  |  |  | $ | (605) |  | $ | 20,614
Operating expenses, as previously reported |  | $ | 938 |  | $ | 12,661 |  | $ | 686 |  | $ | (53) |  | $ | 14,232
Adjustments |  |  | 37 |  |  | (55) |  |  | (9) |  |  | — |  |  | (27)
Operating expenses, as adjusted |  | $ | 975 |  | $ | 12,606 |  | $ | 677 |  | $ | (53) |  | $ | 14,205
Operating profit (loss), as previously reported |  | $ | 3,272 |  | $ | 4,375 |  | $ | (686) |  | $ | (552) |  | $ | 6,409
Adjustments |  |  | (76) |  |  | 67 |  |  | 9 |  |  | — |  |  | —
Operating profit (loss), as adjusted |  | $ | 3,196 |  | $ | 4,442 |  | $ | (677) |  | $ | (552) |  | $ | 6,409

24

Table of Contents

The following is a reconciliation of the Company’s segments to the accompanying condensed consolidated financial statements:

|  | Pharmacy |  |  |  |  |  |  |  | Intersegment |  | Consolidated
In millions |  | Services(1) |  | Retail/LTC |  | Corporate |  | Eliminations(2) |  | Totals
Three Months Ended |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
September 30, 2018: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenues |  | $ | 33,763 |  | $ | 20,856 |  | $ | — |  | $ | (7,350) |  | $ | 47,269
Gross profit |  |  | 1,737 |  |  | 5,814 |  |  | — |  |  | (223) |  |  | 7,328
Operating profit (loss) (4)(6) |  |  | 1,345 |  |  | 1,491 |  |  | (287) |  |  | (196) |  |  | 2,353
September 30, 2017: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenues |  |  | 32,896 |  |  | 19,593 |  |  | — |  |  | (6,308) |  |  | 46,181
Gross profit (5) |  |  | 1,632 |  |  | 5,689 |  |  | — |  |  | (204) |  |  | 7,117
Operating profit (loss) (3)(4)(6) |  |  | 1,327 |  |  | 1,581 |  |  | (222) |  |  | (187) |  |  | 2,499
Nine Months Ended |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
September 30, 2018: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenues |  | $ | 99,228 |  | $ | 61,960 |  | $ | — |  | $ | (21,518) |  | $ | 139,670
Gross profit |  |  | 4,370 |  |  | 17,642 |  |  | — |  |  | (624) |  |  | 21,388
Operating profit (loss) (3)(4)(6) |  |  | 3,194 |  |  | 890 |  |  | (814) |  |  | (558) |  |  | 2,712
September 30, 2017: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenues |  |  | 96,444 |  |  | 58,488 |  |  | — |  |  | (18,552) |  |  | 136,380
Gross profit (5) |  |  | 4,171 |  |  | 17,048 |  |  | — |  |  | (605) |  |  | 20,614
Operating profit (loss) (3)(4)(6) |  |  | 3,196 |  |  | 4,442 |  |  | (677) |  |  | (552) |  |  | 6,409

| (1) |  | Net revenues of the Pharmacy Services Segment include approximately $2.7 billion and $2.6 billion of retail co‑payments for the three months ended September 30, 2018 and 2017, respectively, as well as $8.8 billion and $8.4 billion of retail co‑payments for the nine months ended September 30, 2018 and 2017, respectively.

| (2) |  | Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients (“members”) fill prescriptions at the Company’s retail pharmacies to purchase covered products, when members enrolled in programs such as Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail, or when members have prescriptions filled at the Company’s long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a stand-alone basis.

| (3) |  | The Retail/LTC Segment operating profit for the nine months ended September 30, 2018 and 2017 include goodwill impairment charges of $3.9 billion related to the LTC reporting unit and $135 million related to the RxCrossroads reporting unit, respectively. See “Note 3 – Goodwill and Intangible Assets” to the condensed consolidated financial statements. The Retail/LTC Segment operating profit for the nine months ended September 30, 2018 also includes an $86 million loss on the divestiture of the RxCrossroads subsidiary. The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2017 also includes $6 million and $211 million, respectively, of charges associated with store closures.

| (4) |  | The Corporate Segment operating loss for the three and nine months ended September 30, 2018 include $66 million and $145 million, respectively, in acquisition-related transaction and integration costs related to the proposed acquisition of Aetna. The Corporate Segment operating loss for the three and nine months ended September 30, 2017 include $3 million reduction in integration costs for a change in estimate related to the acquisition of Omnicare.

| (5) |  | The Retail/LTC Segment gross profit for the three and nine months ended September 30, 2017 include $2 million and $7 million, respectively, of acquisition-related integration costs related to the acquisition of Omnicare.

| (6) |  | The Retail/LTC Segment operating profit for the three months ended September 30, 2018 and 2017 include $4 million and $9 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the nine months ended September 30, 2018 and 2017 include $7 million and $34 million, respectively, of acquisition-related integration costs. The integration costs are related to the acquisition of Omnicare.

25

Table of Contents

Note 11 – Commitments and Contingencies

Lease Guarantees

Between 1995 and 1997, the Company sold or spun off a number of subsidiaries, including Bob’s Stores, Linens ‘n Things, and Marshalls. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the store’s lease obligations. When the subsidiaries were disposed of and accounted for as discontinued operations, the Company’s guarantees remained in place, although each initial purchaser has agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries were to become insolvent and failed to make the required payments under a store lease, the Company could be required to satisfy these obligations. As of September 30, 2018, the Company guaranteed approximately 84 such store leases (excluding the lease guarantees related to Linens ‘n Things, which have been recorded as a liability on the condensed consolidated balance sheet), with the maximum remaining lease term extending through 2029.

Legal Matters

The Company is a party to legal proceedings, investigations and claims in the ordinary course of its business, including the matters described below. The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and estimable, the Company does not establish an accrued liability. None of the Company’s accruals for outstanding legal matters are material individually or in the aggregate to the Company’s financial position.

Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters.

| · |  | Indiana State District Council of Laborers and HOD Carriers Pension and Welfare Fund v. Omnicare, Inc., et al. (U.S. District Court for the Eastern District of Kentucky). In February 2006, two substantially similar putative class action lawsuits were filed and subsequently consolidated. The consolidated complaint was filed against Omnicare, three of its officers and two of its directors and purported to be brought on behalf of all open-market purchasers of Omnicare common stock from August 3, 2005 through July 27, 2006, as well as all purchasers who bought shares of Omnicare common stock in Omnicare’s public offering in December 2005. The complaint alleged violations of the Securities Exchange Act of 1934 and Section 11 of the Securities Act of 1933 and sought, among other things, compensatory damages and injunctive relief. After dismissals and appeals to the United States Court of Appeals for the Sixth Circuit, the United States Supreme Court remanded the case to the district court. In October 2016, Omnicare filed an answer to plaintiffs’ third amended complaint, and discovery commenced. In October 2018, the Company agreed to resolve this matter for $20 million, funded by insurance proceeds. The settlement is subject to the parties reaching agreement on the non-economic terms and court approval. The Company denies any wrongdoing, and agreed to a settlement to avoid the burden, uncertainty and distraction of litigation.

26

Table of Contents

| · |  | United States ex rel. Jack Chin v. Walgreen Company, et al. (U.S. District Court for the Central District of California). In March 2010, the Company received a subpoena from the U.S. Department of Health and Human Services, Office of the Inspector General requesting information about programs under which the Company has offered customers remuneration conditioned upon the transfer of prescriptions for drugs or medications to the Company’s pharmacies in the form of gift cards, cash, non-prescription merchandise or discounts or coupons for non-prescription merchandise. In October 2016, the U.S. District Court for the Central District of California unsealed a qui tam complaint, filed in April 2009 against CVS Pharmacy and other retail pharmacies, alleging that the Company violated the federal False Claims Act, and the False Claims Acts of several states, by offering such programs. The complaint was served on the Company in January 2017. In December 2017, the same court unsealed a second qui tam complaint filed by the same relator in September 2017. The complaint is based on the same factual allegations but asserts a legal theory the Court did not permit him to add to the original case. The federal government has declined intervention in both cases. In April 2018, the Court dismissed the second lawsuit. In May 2018, the Court allowed the relator’s motion to amend the complaint to add additional related legal theories, one of which was subsequently dismissed in July 2018. The Company is defending the matter.

| · |  | State of Texas ex rel. Myron Winkelman and Stephani Martinson, et al. v. CVS Health Corporation (Travis County Texas District Court). In February 2012, the Attorney General of the State of Texas issued Civil Investigative Demands and has issued a series of subsequent requests for documents and information in connection with its investigation concerning the CVS Health Savings Pass program and other pricing practices with respect to claims for reimbursement from the Texas Medicaid program. In January 2017, the Court unsealed a first amended petition. The amended petition alleges the Company violated the Texas Medicaid Fraud Prevention Act by submitting false claims for reimbursement to Texas Medicaid by, among other things, failing to use the price available to members of the CVS Health Savings Pass program as the usual and customary price. The amended petition was unsealed following the Company’s filing of CVS Pharmacy, Inc. v. Charles Smith, et al. (Travis County District Court), a declaratory judgment action against the State of Texas in December 2016 seeking a declaration that the prices charged to members of the CVS Health Savings Pass program do not constitute usual and customary prices under the Medicaid regulation. In March 2018, the Court denied the State of Texas’s request for temporary injunctive relief. The cases are proceeding.

| · |  | Corcoran et al. v. CVS Health Corporation (U.S. District Court for the Northern District of California) and Podgorny et al. v. CVS Health Corporation (U.S. District Court for the Northern District of Illinois). These putative class actions were filed against the Company in July and September 2015. The cases were consolidated in United States District Court in the Northern District of California. Plaintiffs seek damages and injunctive relief on behalf of a class of consumers who purchased certain prescription drugs under the consumer protection statutes and common laws of certain states. Several third-party payors filed similar putative class actions on behalf of payors captioned Sheet Metal Workers Local No. 20 Welfare and Benefit Fund v. CVS Health Corp. and Plumbers Welfare Fund, Local 130 v. CVS Health Corporation (both pending in the U.S. District Court for the District of Rhode Island) in February and August 2016. In all of these cases the plaintiffs allege the Company overcharged for certain prescription drugs by not submitting the price available to members of the CVS Health Savings Pass program as the pharmacy’s usual and customary price. In the consumer case (Corcoran), the Court granted summary judgment to CVS on plaintiffs’ claims in their entirety and certified certain subclasses in September 2017. The Corcoran plaintiffs have appealed to the Ninth Circuit. The Sheet Metal plaintiffs have amended their complaint to assert a Racketeer Influenced and Corrupt Organizations Act claim premised on an alleged conspiracy between the Company and other PBMs. The Company continues to defend these actions.

| · |  | Omnicare DEA Subpoena. In September 2015, Omnicare was served with an administrative subpoena by the U.S. Drug Enforcement Administration (“DEA”). The subpoena seeks documents related to controlled substance policies, procedures, and practices at eight pharmacy locations from May 2012 to the present. In September 2017, the DEA expanded the investigation to include an additional pharmacy. The Company has been cooperating and providing documents and witnesses in response to this administrative subpoena.

| · |  | Omnicare Cycle Fill Civil Investigative Demand. In October 2015, Omnicare received a Civil Investigative Demand from the United States Attorney’s Office for the Southern District of New York requesting information and documents concerning Omnicare’s cycle fill process for assisted living facilities. The Company has been cooperating with the government and providing documents and information in response to the Civil

27

Table of Contents

Investigative Demand. In July 2017, Omnicare also received a subpoena from the California Department of Insurance requesting documents on similar subject matter.

| · |  | United States ex rel. Sally Schimelpfenig and John Segura v. Dr. Reddy's Laboratories Limited and Dr. Reddy's Laboratories, Inc. (U.S. District Court for the Eastern District of Pennsylvania). In November 2015, the Court unsealed a second amended qui tam complaint filed in September 2015. The U.S. Department of Justice (“DOJ”) declined to intervene in this action. The relators allege that the Company, Walgreens, Wal-Mart, and Dr. Reddy’s Laboratories violated the federal and various state False Claims Acts by dispensing prescriptions in unit dose packaging supplied by Dr. Reddy’s that was not compliant with the Consumer Product Safety Improvement Act and the Poison Preventive Packaging Act and thereby allegedly rendering the drugs misbranded under the Food, Drug and Cosmetic Act. In March 2017, the Court granted the Company’s motion to dismiss with leave to file an amended complaint. In March 2018, the Court granted the Company’s motion to dismiss an amended complaint with prejudice. In June 2018, the relators filed a notice of appeal. The relators dismissed their appeal, and the case is now closed.

| · |  | State of California ex rel. Matthew Omlansky v. CVS Caremark Corporation (Superior Court of the State of California, County of Sacramento). In April 2016, the court unsealed a first amended qui tam complaint filed in July 2013. The government has declined intervention in this case. The relator alleges that the Company submitted false claims for payment to California Medicaid in connection with reimbursement for drugs available through the CVS Health Savings Pass program as well as certain other generic drugs. The case has been stayed pending the relator’s appeal of the judgment against him in a similar case against another retailer.

| · |  | Retail DEA Matters. The Company has been undergoing several audits by the DEA Administrator and is in discussions with the DEA and the U.S. Attorney’s Offices in several locations concerning allegations that the Company has violated certain requirements of the Controlled Substance Act.

| · |  | National Opioid Litigation. In December 2017, the United States Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against various defendants by plaintiffs such as counties, cities, hospitals, Indian tribes, and third-party payors, alleging claims generally concerning the impacts of widespread opioid abuse. The consolidated multidistrict litigation captioned In re National Prescription Opiate Litigation (MDL No. 2804) is pending in the U.S. District Court for the Northern District of Ohio. This multidistrict litigation presumptively includes hundreds of relevant federal court cases that name the Company. Fewer than 100 similar cases that name the Company in some capacity are pending in state courts. The Company is defending all such federal and state matters. Additionally, the Company has received from the Attorney Generals of several states subpoenas, civil investigative demands, and/or other requests concerning opioids.

| · |  | State of Mississippi v. CVS Health Corporation, et al. (Chancery Court of DeSoto County, Mississippi, Third Judicial District). In July 2016, the Company was served with a complaint filed on behalf of the State of Mississippi alleging that CVS retail pharmacies in Mississippi submitted false claims for reimbursement to Mississippi Medicaid by not submitting the price available to members of the CVS Health Savings Pass program as the pharmacy’s usual and customary price. The Company has responded to the complaint, filed a counterclaim, and moved to transfer the case to circuit court. The motion to transfer was granted and the motion to dismiss remains pending.

| · |  | Part B Insulin Products Civil Investigative Demand. In December 2016, the Company received a Civil Investigative Demand from the U.S. Attorney’s Office for the Northern District of New York, requesting documents and information in connection with a False Claims Act investigation concerning whether the Company’s retail pharmacies improperly submitted certain insulin claims to Medicare Part D rather than Part B. The Company has cooperated with the government and provided documents and information in response to the Civil Investigative Demand.

| · |  | Cold Chain Logistics Civil Investigative Demand. In September 2016, the Company received from the DOJ a Civil Investigative Demand in connection with an investigation as to whether the Company’s handling of certain temperature-sensitive pharmaceuticals violates the federal Food, Drug and Cosmetic Act and the False Claims Act. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.

28

Table of Contents

| · |  | Insulin Products Investigation. In April 2017, the Company received a Civil Investigative Demand from the Attorney General of Washington, seeking documents and information regarding pricing and rebates for insulin products in connection with a pending investigation into unfair and deceptive acts or practice regarding insulin pricing. We have been notified by the Office of the Attorney General of Washington that information provided in response to the Civil Investigative Demand will be shared with the Attorneys General of California, Florida, Minnesota, New Mexico, the District of Columbia, and Mississippi. In July 2017, the Company received a Civil Investigative Demand from the Attorney General of Minnesota, seeking documents and information regarding pricing and rebates for insulin and epinephrine products in connection with a pending investigation into unfair and deceptive acts or practices regarding insulin and epinephrine pricing.

| · |  | Bewley, et al. v. CVS Health Corporation, et al. and Prescott, et al. v. CVS Health Corporation, et al. (both pending in the U.S. District Court for the Western District of Washington). These putative class actions were filed in May 2017 against the Company and other pharmacy benefit managers and manufacturers of glucagon kits (Bewley) and diabetes test strips (Prescott). Both cases allege that, by contracting for rebates with the manufacturers of these diabetes products, the Company and other PBMs caused list prices for these products to increase, thereby harming certain consumers. The primary claims are made under federal antitrust laws, the federal Racketeer Influenced and Corrupt Organizations Act (“RICO”), state unfair competition and consumer protection laws, and the federal Employee Retirement Income Security Act (“ERISA”). These cases have both been transferred to the United States District Court for the District of New Jersey on defendants’ motions. The Company is defending these lawsuits.

| · |  | Klein, et al. v. Prime Therapeutics, et al. (U.S. District Court for the District of Minnesota). In June 2017, a putative class action complaint was filed against the Company and other pharmacy benefit managers on behalf of ERISA plan members who purchased and paid for EpiPen or EpiPen Jr. Plaintiffs allege that the pharmacy benefit managers are ERISA fiduciaries to plan members and have violated ERISA by allegedly causing higher inflated prices for EpiPen through the process of negotiating increased rebates from EpiPen manufacturer, Mylan. This case was recently consolidated with a similar matter and is now proceeding as In re EpiPen ERISA Litigation. The Company is defending the lawsuit.

| · |  | Medicare Part D Civil Investigative Demand. In May 2017, the United States Attorney’s Office for the Southern District of New York issued a Civil Investigative Demand to the Company concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.

| · |  | Shareholder Matters. In August and September 2017, four complaints were filed by putative derivative plaintiffs against certain officers and directors of the Company. Three of those actions, Sherman v. Merlo, et al., Feghali v. Merlo, et al., and Banchalter v. Merlo, et al., were filed in the U.S. District Court for the District of Rhode Island. A fourth, Boron v. Bracken, et al., was filed in Rhode Island Superior Court. These matters assert a variety of causes of action, including breach of fiduciary duty, waste of corporate assets, unjust enrichment, civil conspiracy and violation of Section 14(a) of the Exchange Act, and are premised on the allegation that the defendants approved business plans that exposed the Company to various litigations and investigations. The three federal matters have been stayed pending resolution of certain of the underlying matters, and the Company has filed a motion to dismiss the state court action.

The Company is also a party to other legal proceedings, government investigations, inquiries and audits, and has received and is cooperating with subpoenas or similar process from various governmental agencies requesting information, all arising in the normal course of its business, none of which is expected to be material to the Company. The Company can give no assurance, however, that its business, financial condition and results of operations will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or regulations as they may relate to the Company’s business, the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industries or to the health care industry generally; (iii) pending or future federal or state governmental investigations of the Company’s business or the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or of the health care industry generally; (iv) pending or future government enforcement actions against the Company; (v) adverse developments in any pending qui tam lawsuit against the Company, whether sealed or unsealed, or in any future qui tam lawsuit that may be filed

29

Table of Contents

against the Company; or (vi) adverse developments in pending or future legal proceedings against the Company or affecting the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or the health care industry generally.

30

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of CVS Health Corporation

Results of Review of Interim Financial Statements

We have reviewed the accompanying condensed consolidated balance sheet of CVS Health Corporation (the Company) as of September 30, 2018, the related condensed consolidated statements of operations and comprehensive income for the three-month and nine-month periods ended September 30, 2018 and 2017, the condensed consolidated statements of cash flows for the nine-month periods ended September 30, 2018 and 2017, and the related notes (collectively referred to as the “condensed consolidated interim financial statements”). Based on our reviews, we are not aware of any material modifications that should be made to the condensed consolidated interim financial statements for them to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet of the Company as of December 31, 2017, the related consolidated statements of income, comprehensive income, shareholders’ equity and cash flows for the year then ended, and the related notes (not presented herein); and in our report dated February 14, 2018, we expressed an unqualified audit opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2017, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

Basis for Review Results

These financial statements are the responsibility of the Company’s management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the company in accordance with the U.S. federal securities law and the applicable rules and regulations of the SEC and the PCAOB. We conducted our review in accordance with the standards of the PCAOB. A review of interim financial statements consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

/s/ Ernst & Young LLP |
Boston, Massachusetts |
November 6, 2018 |

31

Table of Contents

Part I | Item 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview of Our Business

CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health,” the “Company,” “we,” “our” or “us”), is a pharmacy innovation company helping people on their path to better health. At the forefront of a changing health care landscape, the Company has an unmatched suite of capabilities and the expertise needed to drive innovations that will help shape the future of health care.

We are currently the only integrated pharmacy health care company with the ability to impact consumers, payors, and providers with innovative, channel-agnostic solutions. We have a deep understanding of their diverse needs through our unique integrated model, and we are bringing them innovative solutions that help increase access to quality care, deliver better health outcomes and lower overall health care costs.

Through more than 9,800 retail locations, approximately 1,100 retail health care clinics, a leading pharmacy benefits manager with approximately 93 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services and a leading stand-alone Medicare Part D prescription drug plan, we enable people, businesses, and communities to manage health in more affordable, effective ways. We are delivering break-through products and services, from advising patients on their medications at our CVS Pharmacy® locations, to introducing unique programs to help control costs for our clients at CVS Caremark®, to innovating how care is delivered to our patients with complex conditions through CVS Specialty®, to improving pharmacy care for the senior community through Omnicare®, or by expanding access to high-quality, low-cost care at CVS MinuteClinic®.

We have three reportable segments: Pharmacy Services, Retail/LTC and Corporate.

Pharmacy Services Segment

Our PSS provides prescription drugs to plan members through mail order pharmacies, specialty pharmacies and a national network of retail pharmacies. Additional services are also offered to clients, including administration and formulary management, Medicare Part D services, infusion services, prescription management systems, clinical services, disease management services and medical spend management. Our clients are primarily employers, insurance companies, unions, government employee groups, health plans, Medicare Part D plans, Managed Medicaid plans, plans offered on the public and private exchanges, and other sponsors of health benefit plans and individuals throughout the United States.

Our clients are primarily employers, insurance companies, unions, government employee groups, health plans, Medicare Part D plans, Managed Medicaid plans, plans offered on the public and private exchanges, other sponsors of health benefit plans and individuals throughout the United States. A portion of covered lives, primarily within the Managed Medicaid, health plan and employer markets have access to our services through public and private exchanges.

As a pharmacy benefits manager, we manage the dispensing of prescription drugs through our mail order pharmacies, specialty pharmacies, national network of long-term care pharmacies and more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies (which includes our CVS Pharmacy® pharmacies) and 27,000 independent pharmacies, to eligible members in the benefit plans maintained by our clients and utilize our information systems to perform, among other things, safety checks, drug interaction screenings and brand-to-generic substitutions.

Our specialty pharmacies support individuals who require complex and expensive drug therapies. Our specialty pharmacy business includes mail order and retail specialty pharmacies that operate primarily under the CVS Caremark®, Navarro® Health Services and Advanced Care Scripts TM (“ACS Pharmacy”) names. The Pharmacy Services Segment also provides health management programs, which include integrated disease management for 19 conditions, through our AccordantCare TM rare disease management offering. In addition, through our SilverScript Insurance Company subsidiary, we are a national provider of drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program. The Pharmacy Services Segment operates primarily under the CVS Caremark® Pharmacy Services, Caremark®, CVS Caremark®, CVS Specialty®, AccordantCare TM, SilverScript®, Wellpartner®, Coram®, NovoLogix®, Navarro® Health Services and ACS Pharmacy TM names. As of September 30, 2018, the Pharmacy Services Segment

32

Table of Contents

operated 25 retail specialty pharmacy stores, 17 specialty mail order pharmacies, four mail order dispensing pharmacies, and 86 branches for infusion and enteral services, including approximately 68 ambulatory infusion suites and three centers of excellence, located in 42 states, Puerto Rico and the District of Columbia.

Retail/LTC Segment

Our Retail/LTC Segment sells prescription drugs and a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, seasonal merchandise, greeting cards and photo finishing, through our CVS Pharmacy®, CVS®, CVS Pharmacy y más®, Longs Drugs®, Navarro Discount Pharmacy® and Drogaria Onofre TM retail locations and online through CVS.com®, Navarro.com TM and Onofre.com.br TM. The Retail/LTC Segment also includes the long-term care operations of Omnicare, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. The Retail/LTC operations also included commercialization services which were provided under the name RxCrossroads® (“RxC”), until the sale of RxC was completed on January 2, 2018. See “Note 3 – Goodwill and Intangible Assets” to the condensed consolidated financial statements for more information. Our Retail/LTC Segment derives the majority of its revenues through the sale of prescription drugs, which are dispensed by our nearly 32,000 pharmacists. Our Retail/LTC Segment also provides health care services through our MinuteClinic® health care clinics. MinuteClinics are staffed by nurse practitioners and physician assistants who utilize nationally recognized protocols to diagnose and treat minor health conditions, perform health screenings, monitor chronic conditions and deliver vaccinations. As of September 30, 2018, our Retail/LTC Segment included 9,905 retail stores (of which 8,149 were our stores that operated a pharmacy and 1,709 were our pharmacies located within Target stores) located in 49 states, the District of Columbia, Puerto Rico and Brazil operating primarily under the CVS Pharmacy®, CVS®, CVS Pharmacy y más®, Longs Drugs®, Navarro Discount Pharmacy® and Drogaria Onofre TM names, 37 onsite pharmacies primarily operating under the CarePlus CVS Pharmacy®, CarePlus® and CVS Pharmacy® names, 1,102 retail health care clinics operating under the MinuteClinic® name (of which 1,098 were located in our retail pharmacy stores or Target stores), and our online retail websites, CVS.com®, Navarro.com TM and Onofre.com.br TM. LTC operations are comprised of 155 spoke pharmacies that primarily handle new prescription orders, of which 30 are also hub pharmacies that use proprietary automation to support spoke pharmacies with refill prescriptions. LTC operates primarily under the Omnicare® and NeighborCare® names.

Corporate Segment

The Corporate Segment provides management and administrative services to support the Company. The Corporate Segment consists of certain aspects of our executive management, corporate relations, legal, compliance, human resources, information technology and finance departments.

Results of Operations

The following discussion explains the material changes in our results of operations for the three and nine months ended September 30, 2018 and 2017, and the significant developments affecting our financial condition since December 31, 2017. We strongly recommend that you read our audited consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included as Exhibit 13 to our 2017 Form 10‑K along with this report.

33

Table of Contents

Summary of the Condensed Consolidated Financial Results:

|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
In millions, except per share amounts |  | 2018 |  | 2017 (1) |  | 2018 |  | 2017 (1)
Net revenues |  | $ | 47,269 |  | $ | 46,181 |  | $ | 139,670 |  | $ | 136,380
Cost of revenues |  |  | 39,941 |  |  | 39,064 |  |  | 118,282 |  |  | 115,766
Gross profit |  |  | 7,328 |  |  | 7,117 |  |  | 21,388 |  |  | 20,614
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  | — |  |  | — |  |  | 3,921 |  |  | 135
Other operating expenses |  |  | 4,975 |  |  | 4,618 |  |  | 14,755 |  |  | 14,070
Operating profit |  |  | 2,353 |  |  | 2,499 |  |  | 2,712 |  |  | 6,409
Interest expense, net |  |  | 453 |  |  | 245 |  |  | 1,401 |  |  | 744
Other expense |  |  | 1 |  |  | 192 |  |  | 7 |  |  | 206
Income before income tax provision |  |  | 1,899 |  |  | 2,062 |  |  | 1,304 |  |  | 5,459
Income tax provision |  |  | 509 |  |  | 777 |  |  | 1,478 |  |  | 2,115
Income (loss) from continuing operations |  |  | 1,390 |  |  | 1,285 |  |  | (174) |  |  | 3,344
Loss from discontinued operations, net of tax |  |  | — |  |  | — |  |  | (1) |  |  | (8)
Net income (loss) |  |  | 1,390 |  |  | 1,285 |  |  | (175) |  |  | 3,336
Net income attributable to noncontrolling interests |  |  | — |  |  | — |  |  | — |  |  | (1)
Net income (loss) attributable to CVS Health |  | $ | 1,390 |  | $ | 1,285 |  | $ | (175) |  | $ | 3,335

| (1) |  | Financial information for the three and nine months ended September 30, 2017 has been retrospectively adjusted to reflect a change to the Company’s cost allocation methodology effective January 1, 2018. See “Note 10 – Segment Reporting” to the condensed consolidated financial statements for further discussion.

Net Revenues

Net revenues increased approximately $1.1 billion, or 2.4%, and $3.3 billion, or 2.4%, in the three and nine months ended September 30, 2018, respectively, as compared to the prior year. The increase is due to growth in pharmacy network claim volume in the Pharmacy Services Segments and increased prescription volume in the Retail/LTC Segment, as well as brand inflation. The increases were partially offset by continued price compression and reimbursement pressure as well as increased generic dispensing. Generic prescription drugs typically have a lower selling price than brand name prescription drugs.

Please see the section entitled “Segment Analysis” below for additional information regarding net revenues.

Gross Profit

Gross profit dollars increased $211 million, or 3.0%, and $774 million, or 3.8%, in the three and nine months ended September 30, 2018, respectively, as compared to the prior year. Gross profit dollars for the three and nine months ended September 30, 2018 were positively impacted by increased prescription volume, improved purchasing economics and increased generic dispensing in both segments, partially offset by continued reimbursement pressure and pricing compression. Gross profit as a percentage of net revenues increased approximately ten basis points in the three months ended September 30, 2018 to 15.5%, as compared to the prior year. Gross profit as a percentage of net revenues increased approximately 20 basis points in the nine months ended September 30, 2018 to 15.3%, as compared to the prior year.

Please see the section entitled “Segment Analysis” below for additional information regarding gross profit.

34

Table of Contents

Operating Expenses

Operating expenses including goodwill impairments increased $357 million, or 7.7%, and $4.5 billion, or 31.5%, in the three and nine months ended September 30, 2018, respectively, as compared to the prior year. Operating expenses as a percentage of net revenues increased approximately 50 and 300 basis points in the three and nine months ended September 30, 2018, respectively, as compared to the prior year. The increase in operating expenses in the three and nine months ended September 30, 2018 was primarily due to the following:

| · |  | Goodwill impairments increased $3.8 billion in the nine months ended September 30, 2018, due to a goodwill impairment charge of $3.9 billion in the LTC reporting unit in the nine months ended September 30, 2018 (see “Note 3 – Goodwill and Intangible Assets” to our condensed consolidated financial statements), compared to a $135 million goodwill impairment charge in the RxC reporting unit recorded in the nine months ended September 30, 2017 in connection with the possible sale of RxC. See further discussion of goodwill under “Critical Accounting Policies” later in this document.

| · |  | An $86 million loss in the nine months ended September 30, 2018 on the divestiture of our RxCrossroads subsidiary included in our Retail/LTC Segment.

| · |  | An increase in acquisition-related transaction and integration costs of $66 million and $128 million in the three and nine months ended September 30, 2018, respectively, versus the same periods in the prior year.

| · |  | An increase in operating expenses in the Pharmacy Services and Retail/LTC segments as discussed under “Segment Analysis” later in this document.

These items were partially offset by:

| · |  | A decrease in operating expenses as a result of a lack of charges associated with store closures in the three and nine months ended September 30, 2018, for which we incurred $6 million and $211 million in connection with our enterprise streamlining initiatives in the three and nine months ended September 30, 2017, respectively.

| · |  | A decrease in hurricane-related expenses of $42 million in the three and nine months ended September 30, 2018.

Please see the section entitled “Segment Analysis” below for additional information regarding operating expenses.

Interest Expense, net

Interest expense, net, increased $208 million and $657 million in the three and nine months ended September 30, 2018, respectively, as compared to the prior year. The increase in the three and nine months ended September 30, 2018 was primarily due to the amortization of bridge facility fees of $2 million and $171 million, respectively, for the unsecured bridge facility entered into in December 2017, as well as interest expense of $434 million and $979 million, respectively, on the $40 billion of senior notes issued in March 2018 and the $5 billion term loan facility. These increases were partially offset by interest income on the investment of the proceeds of the $40 billion debt issuance of $209 million and $453 million, respectively, in the three and nine months ended September 30, 2018. See “Note 4 - Borrowings and Credit Agreements” to the condensed consolidated financial statements for additional information.

For additional information on our financing activities, please see the “Liquidity and Capital Resources” section below.

35

Table of Contents

Other Expenses

Other expenses decreased $191 million and $199 million in the three and nine months ended September 30, 2018, respectively, as compared to the prior year. The decrease in the three and nine months ended was primarily driven by the losses on the settlements of defined benefit pension plans of $187 million in the prior year periods.

Income Tax Provision

Our effective income tax rate was 26.8% and 113.3% for the three and nine months ended September 30, 2018, respectively, compared to 37.7% and 38.7% for the three and nine months ended September 30, 2017, respectively. The difference in the effective income tax rate was primarily due to the $3.9 billion goodwill impairment charge recognized in the nine months ended September 30, 2018, which is not deductible for income tax purposes, as well as the enactment of the TCJA in December 2017, which lowered the 2018 federal corporate income tax rate from 35% to 21%. The Company has not completed its processes to determine the full and final impact of the TCJA. That impact may differ, possibly materially, from the provisional amount recorded for year ended December 31, 2017, due to, among other things, changes in interpretations and assumptions the Company has made, guidance that may be issued and actions the Company may take as a result of the TCJA, and the completion of the Company’s 2017 tax returns.

Loss from Discontinued Operations

The loss from discontinued operations of $8 million for the nine months ended September 30, 2017, was primarily comprised of a $15 million charge (net of tax of $6 million) associated with lease guarantees the Company provided on store lease obligations of Bob’s Stores, a former subsidiary of the Company that filed for bankruptcy subsequent to its disposition. See “Note 11 - Commitments and Contingencies” to the Company’s condensed consolidated financial statements.

36

Table of Contents

Segment Analysis

We evaluate the performance of our Pharmacy Services and Retail/LTC segments based on net revenue, gross profit, operating profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. We evaluate the performance of our Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities.

In conjunction with the Company’s implementation of a new enterprise resource planning system in the first quarter of 2018, the Company changed the manner in which certain shared functional costs are allocated to its reportable segments. Segment financial information for the three and nine months ended September 30, 2017, has been retrospectively adjusted to reflect this change to the cost allocation methodology as shown in “Note 10 – Segment Reporting” to the condensed consolidated financial statements.

The following is a reconciliation of our segments to the condensed consolidated financial statements:

|  | Pharmacy |  |  |  |  |  |  |  | Intersegment |  | Consolidated
In millions |  | Services(1) |  | Retail/LTC |  | Corporate |  | Eliminations(2) |  | Totals
Three Months Ended |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
September 30, 2018: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenues |  | $ | 33,763 |  | $ | 20,856 |  | $ | — |  | $ | (7,350) |  | $ | 47,269
Gross profit |  |  | 1,737 |  |  | 5,814 |  |  | — |  |  | (223) |  |  | 7,328
Operating profit (loss) (4)(6) |  |  | 1,345 |  |  | 1,491 |  |  | (287) |  |  | (196) |  |  | 2,353
September 30, 2017: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenues |  |  | 32,896 |  |  | 19,593 |  |  | — |  |  | (6,308) |  |  | 46,181
Gross profit (5) |  |  | 1,632 |  |  | 5,689 |  |  | — |  |  | (204) |  |  | 7,117
Operating profit (loss) (3)(4)(6) |  |  | 1,327 |  |  | 1,581 |  |  | (222) |  |  | (187) |  |  | 2,499
Nine Months Ended |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
September 30, 2018: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenues |  |  | 99,228 |  |  | 61,960 |  |  | — |  |  | (21,518) |  |  | 139,670
Gross profit |  |  | 4,370 |  |  | 17,642 |  |  | — |  |  | (624) |  |  | 21,388
Operating profit (loss) (3)(4)(6) |  |  | 3,194 |  |  | 890 |  |  | (814) |  |  | (558) |  |  | 2,712
September 30, 2017: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenues |  |  | 96,444 |  |  | 58,488 |  |  | — |  |  | (18,552) |  |  | 136,380
Gross profit (5) |  |  | 4,171 |  |  | 17,048 |  |  | — |  |  | (605) |  |  | 20,614
Operating profit (loss) (3)(4)(6) |  |  | 3,196 |  |  | 4,442 |  |  | (677) |  |  | (552) |  |  | 6,409

| (1) |  | Net revenues of the Pharmacy Services Segment include approximately $2.7 billion and $2.6 billion of retail co‑payments for the three months ended September 30, 2018 and 2017, respectively, as well as $8.8 billion and $8.4 billion of retail co‑payments for the nine months ended September 30, 2018 and 2017, respectively.

| (2) |  | Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients (“members”) fill prescriptions at the Company’s retail pharmacies to purchase covered products, when members enrolled in programs such as Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail, or when members have prescriptions filled at the Company’s long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a stand-alone basis.

| (3) |  | The Retail/LTC Segment operating profit for the nine months ended September 30, 2018 and 2017 include goodwill impairment charges of $3.9 billion related to the LTC reporting unit and $135 million related to the RxCrossroads reporting unit, respectively. See “Note 3 – Goodwill and Intangible Assets” to the condensed consolidated financial statements. The Retail/LTC Segment operating profit for the nine months ended September 30, 2018 also includes an $86 million loss on the divestiture of the RxCrossroads subsidiary. The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2017 also includes $6 million and $211 million, respectively, of charges associated with store closures.

| (4) |  | The Corporate Segment operating loss for the three and nine months ended September 30, 2018 include $66 million and $145 million, respectively, in acquisition-related transaction and integration costs related to the proposed acquisition of Aetna. The Corporate Segment operating loss for the three and nine months ended September 30, 2017 include $3 million reduction in integration costs for a change in estimate related to the acquisition of Omnicare.

| (5) |  | The Retail/LTC Segment gross profit for the three and nine months ended September 30, 2017 include $2 million and $7 million, respectively, of acquisition-related integration costs related to the acquisition of Omnicare.

| (6) |  | The Retail/LTC Segment operating profit for the three months ended September 30, 2018 and 2017 include $4 million and $9 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the nine months ended September 30, 2018 and 2017 include $7 million and $34 million, respectively, of acquisition-related integration costs. The integration costs are related to the acquisition of Omnicare.

37

Table of Contents

Pharmacy Services Segment

The following table summarizes our Pharmacy Services Segment’s performance for the respective periods:

|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30, |
In millions |  | 2018 |  | 2017 |  | 2018 |  | 2017 |
Net revenues |  | $ | 33,763 |  |  | $ | 32,896 |  |  | $ | 99,228 |  |  | $ | 96,444 |
Gross profit |  |  | 1,737 |  |  |  | 1,632 |  |  |  | 4,370 |  |  |  | 4,171 |
Gross profit % of net revenues |  |  | 5.1 | % |  |  | 5.0 | % |  |  | 4.4 | % |  |  | 4.3 | %
Operating expenses |  |  | 392 |  |  |  | 305 |  |  |  | 1,176 |  |  |  | 975 |
Operating expenses % of net revenues |  |  | 1.2 | % |  |  | 0.9 | % |  |  | 1.2 | % |  |  | 1.0 | %
Operating profit |  |  | 1,345 |  |  |  | 1,327 |  |  |  | 3,194 |  |  |  | 3,196 |
Operating profit % of net revenues |  |  | 4.0 | % |  |  | 4.0 | % |  |  | 3.2 | % |  |  | 3.3 | %
Net revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mail choice (1) |  | $ | 11,812 |  |  | $ | 11,590 |  |  | $ | 34,807 |  |  | $ | 33,950 |
Pharmacy network (2)(4) |  |  | 21,183 |  |  |  | 20,519 |  |  |  | 61,303 |  |  |  | 59,447 |
Other (4) |  |  | 768 |  |  |  | 787 |  |  |  | 3,118 |  |  |  | 3,047 |
Pharmacy claims processed (90 Day = 3 prescriptions) (3): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total |  |  | 466.3 |  |  |  | 441.1 |  |  |  | 1,405.2 |  |  |  | 1,323.2 |
Mail choice (1) |  |  | 71.8 |  |  |  | 66.9 |  |  |  | 213.0 |  |  |  | 196.2 |
Pharmacy network (2) |  |  | 394.5 |  |  |  | 374.2 |  |  |  | 1,192.2 |  |  |  | 1,127.0 |
Generic dispensing rate (3): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total |  |  | 87.2 | % |  |  | 87.0 | % |  |  | 87.5 | % |  |  | 87.1 | %
Mail choice (1) |  |  | 83.9 | % |  |  | 83.3 | % |  |  | 84.0 | % |  |  | 83.1 | %
Pharmacy network (2) |  |  | 87.8 | % |  |  | 87.7 | % |  |  | 88.1 | % |  |  | 87.8 | %
Mail choice penetration rate (3) |  |  | 15.4 | % |  |  | 15.2 | % |  |  | 15.2 | % |  |  | 14.8 | %

| (1) |  | Mail choice is defined as claims filled at a Pharmacy Services mail facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at retail, as well as prescriptions filled at our retail pharmacies under the Maintenance Choice® program.

| (2) |  | Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice activity, which is included within the mail choice category. Pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including our retail pharmacies and long-term care pharmacies, but excluding Maintenance Choice activity.

| (3) |  | Includes the adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.

| (4) |  | Amounts revised for the three and nine months ended September 30, 2017 to reflect the reclassification of Medicare Part D premium revenues from pharmacy network revenues to other revenues.

Net Revenues

Net revenues in our Pharmacy Services Segment increased $867 million, or 2.6%, to $33.8 billion in the three months ended September 30, 2018, as compared to the prior year. Net revenues in our Pharmacy Services Segment increased $2.8 billion, or 2.9%, to $99.2 billion in the nine months ended September 30, 2018, as compared to the prior year. The increase is primarily due to growth in pharmacy network and mail choice claim volume as well as brand inflation, partially offset by continued price compression and increased generic dispensing. As you review our Pharmacy Services Segment’s performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2018:

| · |  | In the three months ended September 30, 2018, our mail choice claims processed, on a 30-day equivalent basis, increased 7.4% to 71.8 million claims compared to 66.9 million claims in the prior year. In the nine months ended September 30, 2018, our mail choice claims processed, on a 30-day equivalent basis, increased 8.6% to 213.0 million claims compared to 196.2 million claims in the prior year. The increase in mail choice claims was primarily driven by the continued adoption of our Maintenance Choice offerings and an increase in specialty pharmacy claims.

| · |  | Our average revenue per mail choice claim, on a 30-day equivalent basis, decreased 5.1% and 5.6% in the three and nine months ended September 30, 2018, respectively, compared to the prior year, as a result of price compression.

38

Table of Contents

| · |  | In the three months ended September 30, 2018, our pharmacy network claims processed, on a 30-day equivalent basis, increased 5.4% to 394.5 million claims compared to 374.2 million claims in the prior year. In the nine months ended September 30, 2018, our pharmacy network claims processed, on a 30-day equivalent basis, increased 5.8% to 1,192.2 million claims compared to 1,127.0 million claims in the prior year. The increase in the pharmacy network claim volume was primarily due to net new business.

| · |  | Our average revenue per pharmacy network claim processed, on a 30-day equivalent basis, decreased 2.3% and 2.6% in the three and nine months ended September 30, 2018, respectively, compared to the prior year.

| · |  | In the three months ended September 30, 2018, our total generic dispensing rate increased to 87.2%, compared to 87.0% in the prior year. In the nine months ended September 30, 2018, our total generic dispensing rate increased to 87.5%, compared to 87.1% in the prior year. The continued increase in our generic dispensing rate was primarily due to the impact of new generic drug introductions and our continuous efforts to encourage plan members to use generic drugs when they are available and clinically appropriate. We believe our generic dispensing rate will continue to increase in future periods, albeit at a slower pace. This increase will be affected by, among other things, the number of new brand and generic drug introductions and our success at encouraging plan members to utilize generic drugs when they are available and clinically appropriate.

Gross Profit

Gross profit in our Pharmacy Services Segment includes net revenues less cost of revenues. Cost of revenues includes (i) the cost of pharmaceuticals dispensed, either directly through our mail service, specialty mail and specialty retail pharmacies or indirectly through our retail pharmacy networks, (ii) shipping and handling costs and (iii) the operating costs of our mail service dispensing pharmacies, customer service operations and related information technology support.

Gross profit increased $105 million, or 6.5%, to approximately $1.7 billion in the three months ended September 30, 2018, as compared to the prior year. Gross profit increased $199 million, or 4.8%, to approximately $4.4 billion in the nine months ended September 30, 2018, as compared to the prior year. The increase in gross profit dollars was primarily due to increased claims volume and improved purchasing economics, partially offset by continued pricing compression. Gross profit as a percentage of net revenues increased approximately 20 basis points to 5.1% in the three months ended September 30, 2018, compared to the prior year. Gross profit as a percentage of net revenues increased approximately ten basis points to 4.4% in the nine months ended September 30, 2018, compared to the prior year.

As you review our Pharmacy Services Segment’s performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2018:

| · |  | Our efforts to (i) retain existing clients, (ii) obtain new business and (iii) maintain or improve the rebates and/or discounts we received from manufacturers, wholesalers and retail pharmacies continue to have an impact on our gross profit dollars and gross profit as a percentage of net revenues. In particular, competitive pressures in the PBM industry have caused us and other PBMs to continue to share with clients a larger portion of rebates and/or discounts received from pharmaceutical manufacturers. In addition, market dynamics and regulatory changes have limited our ability to offer plan sponsors pricing that includes retail network “differential” or “spread,” and we expect these trends to continue. The “differential” or “spread” is any difference between the drug price charged to plan sponsors, including Medicare Part D plan sponsors, by a PBM and the price paid for the drug by the PBM to the dispensing provider.

Operating Expenses

Operating expenses in our Pharmacy Services Segment include selling, general and administrative expenses; depreciation and amortization related to selling, general and administrative activities; and expenses related to specialty retail pharmacies, which include store and administrative payroll, employee benefits and occupancy costs.

Operating expenses increased $87 million, or 28.6%, to $392 million, or 1.2% as a percentage of net revenues, in the three months ended September 30, 2018, compared to $305 million, or 0.9% as a percentage of net revenues, in the prior year. Operating expenses increased $201 million, or 20.5%, to $1.2 billion, or 1.2% as a percentage of net revenues, in the nine months ended September 30, 2018, compared to $975 million, or 1.0% as a percentage of net revenues, in the

39

Table of Contents

prior year. The increase in operating expenses in the three and nine months ended September 30, 2018 is primarily due to growth in the business, including acquisitions, and the reinstatement of the Affordable Care Act’s health insurer fee in 2018, as well as the realization of partially reserved receivables in the prior year periods which reduced operating expenses in those periods.

Retail/LTC Segment

The following table summarizes our Retail/LTC Segment’s performance for the respective periods:

|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30, |
In millions |  | 2018 |  | 2017 |  | 2018 |  |  | 2017 |
Net revenues |  | $ | 20,856 |  |  | $ | 19,593 |  |  | $ | 61,960 |  |  | $ | 58,488 |
Gross profit (1) |  |  | 5,814 |  |  |  | 5,689 |  |  |  | 17,642 |  |  |  | 17,048 |
Gross profit % of net revenues |  |  | 27.9 | % |  |  | 29.0 | % |  |  | 28.5 | % |  |  | 29.1 | %
Operating expenses (2)(3) |  |  | 4,323 |  |  |  | 4,108 |  |  |  | 16,752 |  |  |  | 12,606 |
Operating expenses % of net revenues |  |  | 20.7 | % |  |  | 21.0 | % |  |  | 27.0 | % |  |  | 21.6 | %
Operating profit |  |  | 1,491 |  |  |  | 1,581 |  |  |  | 890 |  |  |  | 4,442 |
Operating profit % of net revenues |  |  | 7.1 | % |  |  | 8.1 | % |  |  | 1.4 | % |  |  | 7.6 | %
Net revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pharmacy |  | $ | 16,123 |  |  | $ | 14,868 |  |  | $ | 47,428 |  |  | $ | 43,901 |
Front Store |  |  | 4,557 |  |  |  | 4,469 |  |  |  | 13,990 |  |  |  | 13,788 |
Other |  |  | 176 |  |  |  | 256 |  |  |  | 542 |  |  |  | 799 |
Prescriptions filled (90 Day = 3 prescriptions) (4) |  |  | 331.2 |  |  |  | 304.0 |  |  |  | 989.7 |  |  |  | 908.7 |
Net revenue increase (decrease): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total |  |  | 6.4 | % |  |  | (2.7) | % |  |  | 5.9 | % |  |  | (2.9) | %
Pharmacy |  |  | 8.4 | % |  |  | (2.9) | % |  |  | 8.0 | % |  |  | (3.1) | %
Front Store |  |  | 2.0 | % |  |  | (2.1) | % |  |  | 1.5 | % |  |  | (2.4) | %
Total prescription volume (90 Day = 3 prescriptions) (4) |  |  | 8.9 | % |  |  | 0.4 | % |  |  | 8.9 | % |  |  | 0.0 | %
Same store sales increase (decrease) (5): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total |  |  | 6.7 | % |  |  | (3.2) | % |  |  | 6.2 | % |  |  | (3.5) | %
Pharmacy |  |  | 8.7 | % |  |  | (3.4) | % |  |  | 8.1 | % |  |  | (3.6) | %
Front Store |  |  | 0.8 | % |  |  | (2.8) | % |  |  | 0.5 | % |  |  | (3.3) | %
Prescription volume (90 Day = 3 prescriptions) (4) |  |  | 9.2 | % |  |  | 0.3 | % |  |  | 9.1 | % |  |  | (0.4) | %
Generic dispensing rates (4) |  |  | 87.3 | % |  |  | 87.2 | % |  |  | 87.8 | % |  |  | 87.4 | %

| (1) |  | Gross profit for the three and nine months ended September 30, 2017 include $2 million and $7 million, respectively, of acquisition-related integration costs related to the acquisition of Omnicare.

| (2) |  | Operating expenses for the three and nine months ended September 30, 2018 include $4 million and $7 million, respectively, of acquisition-related integration costs. Operating expenses for the three and nine months ended September 30, 2017 include $7 million and $27 million, respectively, of acquisition-related integration costs. The integration costs are related to the acquisition of Omnicare.

| (3) |  | Operating expenses for the nine months ended September 30, 2018 and 2017 include goodwill impairment charges of $3.9 billion related to the LTC reporting unit and $135 million related to the RxCrossroads reporting unit, respectively. See “Note 3 – Goodwill and Intangible Assets” to the condensed consolidated financial statements. The operating expenses for the nine months ended September 30, 2018 also includes an $86 million loss on the divestiture of the RxCrossroads subsidiary. Operating expenses for the three and nine months ended September 30, 2017 also include $6 million and $211 million, respectively, of charges associated with store closures.

| (4) |  | Includes the adjustment to convert 90-day non-specialty prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.

| (5) |  | Same store sales and prescriptions exclude revenues from MinuteClinic, and revenue and prescriptions from stores in Brazil, LTC operations and, in 2017, from commercialization services provided through RxCrossroads.

As of September 30, 2018, we operated 9,905 retail locations (of which 8,149 were our stores that operated a pharmacy and 1,709 were our pharmacies located within Target stores), compared to 9,751 retail locations as of September 30, 2017.

40

Table of Contents

Net Revenues

Net revenues in our Retail/LTC Segment increased $1.3 billion, or 6.4%, to approximately $20.9 billion in the three months ended September 30, 2018, as compared to the prior year. Net revenues in our Retail/LTC Segment increased $3.5 billion, or 5.9%, to approximately $62.0 billion in the nine months ended September 30, 2018, as compared to the prior year. As you review our Retail/LTC Segment’s performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2018:

| · |  | Front store same store sales increased by 0.8% and 0.5% for the three and nine months ended September 30, 2018, respectively, compared to the prior year. For the three and nine months ended September 30, 2018, front store same store sales continued to benefit from strength in our consumer health care and beauty care categories.

| · |  | Pharmacy same store sales increased 8.7% and 8.1%, respectively, for the three and nine months ended September 30, 2018. The increase was driven by the increase in pharmacy same store prescription volumes, which increased 9.2% and 9.1%, respectively, for the three and nine months ended September 30, 2018 on a 30-day equivalent basis, due to continued adoption of our Patient Care Programs, alliances with PBMs and health plans, and our inclusion in a number of additional Medicare Part D networks this year, as well as the impact of year over year brand inflation that occurred primarily in the first three months of the year.

| · |  | Pharmacy revenues continue to be negatively impacted by the conversion of brand name drugs to equivalent generic drugs, which typically have a lower selling price. The generic dispensing rate grew to 87.3% and 87.8%, respectively, for the three and nine months ended September 30, 2018, compared to 87.2% and 87.4% for the three and nine months ended September 30, 2017, respectively. In addition, our pharmacy revenue growth has also been negatively affected by continued reimbursement pressure.

| · |  | The results for the three and nine months ended September 30, 2017 include approximately $0.1 billion and $0.3 billion, respectively, related to our RxCrossroads subsidiary which was sold on January 2, 2018.

| · |  | Pharmacy revenue growth has been impacted by industry challenges in the LTC business, such as continuing lower occupancy rates at skilled nursing facilities, as well as the deteriorating financial health of many skilled nursing facilities.

| · |  | Pharmacy revenue continued to benefit from our ability to attract and retain managed care customers, and the increased use of pharmaceuticals by an aging population as the first line of defense for health care.

Gross Profit

Gross profit in our Retail/LTC Segment includes net revenues less the cost of merchandise sold in the period and the related purchasing costs, warehousing costs, delivery costs and actual and estimated inventory losses.

Gross profit increased $125 million, or 2.2%, to $5.8 billion in the three months ended September 30, 2018, as compared to the prior year. Gross profit increased $594 million, or 3.5%, to $17.6 billion in the nine months ended September 30, 2018, as compared to the prior year. Gross profit as a percentage of net revenues decreased to 27.9% in the three months ended September 30, 2018, compared to 29.0% in the prior year. Gross profit as a percentage of net revenues decreased to 28.5% in the nine months ended September 30, 2018, compared to 29.1% in the prior year.

The increase in gross profit dollars was primarily driven by increased volume, improved purchasing economics, partially offset by continued reimbursement pressure. The decrease in gross profit as a percentage of net revenues in the three and nine months ended September 30, 2018 was primarily due to continued pharmacy reimbursement pressure, partially offset by increased front store margins.

As you review our Retail/LTC Segment’s performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2018:

| · |  | Our pharmacy gross profit rates have been adversely affected by the efforts of managed care organizations, PBMs and governmental and other third-party payors to reduce their prescription drug costs, including the use

41

Table of Contents

of restrictive networks, as well as changes in the mix of our business within the pharmacy portion of the Retail/LTC Segment. In the event the reimbursement pressure accelerates, we may not be able grow our revenues and gross profit dollars could be adversely impacted. The increased use of generic drugs has positively impacted our gross profit but has resulted in third-party payors augmenting their efforts to reduce reimbursement payments to retail pharmacies for prescriptions. This trend, which we expect to continue, reduces the benefit we realize from brand to generic product conversions.

Operating Expenses

Operating expenses in our Retail/LTC Segment include payroll and employee benefits, occupancy costs, selling expenses, advertising expenses, depreciation and amortization expense and certain administrative expenses.

Operating expenses increased $215 million to $4.3 billion, or 20.7% as a percentage of net revenues, in the three months ended September 30, 2018, as compared to $4.1 billion, or 21.0% as a percentage of net revenues, in the prior year. Operating expenses increased $4.1 billion to $16.8 billion, or 27.0% as a percentage of net revenues, in the nine months ended September 30, 2018, as compared to $12.6 billion, or 21.6% as a percentage of net revenues, in the prior year. The increase in operating expenses in the three and nine months ended September 30, 2018 was primarily due to the following:

| · |  | A goodwill impairment charge of $3.9 billion in the nine months ended September 30, 2018 in the LTC reporting unit (see “Note 3 – Goodwill and Intangible Assets” to our condensed consolidated financial statements), as compared to a $135 million goodwill impairment charge in the RxC reporting unit recorded in the nine months ended September 30, 2017 in connection with the possible sale of RxC. See further discussion of goodwill under “Critical Accounting Policies” later in this document.

| · |  | An $86 million pre-tax loss on the sale of our RxCrossroads subsidiary in the nine months ended September 30, 2018.

| · |  | An increase in operating expenses in the Retail/LTC Segment due to the investment of savings from the TCJA in wages and benefits, increased prescription volume described previously, incremental costs associated with operating more stores, and investments in the business to drive revenue growth.

These items were partially offset by:

| · |  | A decrease in operating expenses as a result of a lack of charges associated with store closures in the three and nine months ended September 30, 2018, for which we incurred $6 million and $211 million in connection with our enterprise streamlining initiatives in the three and nine months ended September 30, 2017, respectively.

| · |  | A decrease in hurricane-related expenses of $40 million in the three and nine months ended September 30, 2018.

Corporate Segment

Operating Expenses

Operating expenses in our Corporate Segment include expenses from the Company’s executive management, corporate relations, legal, compliance, human resources, information technology and finance departments.

Operating expenses increased $65 million, or 28.8%, to $287 million, and $137 million, or 20.1%, to $814 million, in the three and nine months ended September 30, 2018, respectively, as compared to the prior year. The change in operating expenses was primarily driven by an increase in acquisition-related transaction and integration costs of $69 million and $148 million for the three and nine months ended September 30, 2018, respectively, versus the same period in the prior year. The acquisition-related transaction and integration costs relate to the proposed acquisition of Aetna.

42

Table of Contents

Liquidity and Capital Resources

We maintain a level of liquidity sufficient to allow us to cover our cash needs in the short-term. Over the long-term, we manage our cash and capital structure to maximize shareholder return, maintain our financial position and maintain flexibility for future strategic initiatives. We continuously assess our working capital needs, debt and leverage levels, capital expenditure requirements, dividend payouts, potential share repurchases and future investments or acquisitions. We believe our operating cash flows, commercial paper program, sale-leaseback program, as well as any potential future borrowings, will be sufficient to fund these future payments and long-term initiatives.

The change in cash and cash equivalents and restricted cash is as follows:

|  | Nine Months Ended September 30,
In millions |  | 2018 |  | 2017
Net cash provided by operating activities |  | $ | 6,386 |  | $ | 8,143
Net cash used in investing activities |  |  | (1,386) |  |  | (1,567)
Net cash provided by (used in) financing activities |  |  | 34,927 |  |  | (7,421)
Net increase (decrease) in cash, cash equivalents and restricted cash |  | $ | 39,927 |  | $ | (845)

Net cash provided by operating activities was approximately $6.4 billion in the nine months ended September 30, 2018, compared to $8.1 billion in the nine months ended September 30, 2017. The decrease was primarily driven by the timing of payments from the United States Centers for Medicare and Medicaid Services.

Net cash used in investing activities was approximately $1.4 billion in the nine months ended September 30, 2018, compared to $1.6 billion in the nine months ended September 30, 2017. The $0.2 billion decrease in cash used in investing activities was primarily due to proceeds from the sale of a subsidiary of $0.7 billion partially offset by a $0.2 billion increase in cash outlay for acquisitions and other investments in 2018 versus proceeds from sale-leaseback transactions of approximately $0.3 billion in 2017.

Net cash provided by financing activities was $34.9 billion in the nine months ended September 30, 2018, compared to net cash used in financing activities of $7.4 billion in the nine months ended September 30, 2017. Cash provided by financing activities increased $42.3 billion primarily due to net proceeds from the issuance of long-term debt of $39.4 billion, a $4.4 billion decrease in share repurchases in the current year due to the suspension of the share repurchase program, $0.4 billion received in connection with interest rate hedge settlements, partially offset by a net increase in debt repayments of $1.8 billion.

The following share repurchase programs have been authorized by the Company’s Board of Directors:

In billions |  |  |  |  | Remaining as of
Authorization Date |  | Authorized |  | September 30, 2018
November 2, 2016 (“2016 Repurchase Program”) |  | $ | 15.0 |  | $ | 13.9
December 15, 2014 (“2014 Repurchase Program”) |  |  | 10.0 |  |  | —

The share Repurchase Programs, each of which was effective immediately, permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (“ASR”) transactions, and/or other derivative transactions. The 2014 Repurchase Program was completed during the second quarter of 2017. The 2016 Repurchase Program can be modified or terminated by the Board of Directors at any time.

During the nine months ended September 30, 2018, the Company did not repurchase any shares of common stock pursuant to the 2016 Repurchase Program.

Pursuant to the authorization under the 2014 Repurchase Program, effective August 29, 2016, the Company entered into two fixed dollar ASRs with Barclays Bank PLC (“Barclays”) for a total of $3.6 billion. Upon payment of the $3.6 billion purchase price on January 6, 2017, the Company received a number of shares of its common stock equal to 80% of the $3.6 billion notional amount of the ASRs or approximately 36.1 million shares, which were placed into treasury stock in January 2017. The ASRs were accounted for as an initial treasury stock transaction for $2.9 billion and a forward contract for $0.7 billion. In April 2017, the Company received 9.9 million shares of common stock, representing the

43

Table of Contents

remaining 20% of the $3.6 billion notional amount of the ASRs, thereby concluding the ASRs. The remaining 9.9 million shares of common stock delivered to the Company by Barclays were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in April 2017.

At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share.

The Company did not have any commercial paper outstanding as of September 30, 2018. In connection with its commercial paper program, the Company maintains a $1.75 billion 364-day unsecured back-up credit facility, which expires on May 16, 2019, a $1.25 billion, five-year unsecured back-up credit facility, which expires on July 1, 2020, a $1.0 billion, five-year unsecured back-up credit facility, which expires on May 18, 2022, and a $2.0 billion, five-year unsecured back-up credit facility, which expires on May 17, 2023. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company’s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of September 30, 2018, there were no borrowings outstanding under the back-up credit facilities.

On March 9, 2018, the Company issued an aggregate of $40.0 billion of floating rate notes and unsecured senior notes, collectively the “Notes”, for total proceeds of approximately $39.4 billion, net of discounts and underwriting fees, comprised of the following:

In millions |  |  |
3.125% senior notes due 2020 |  | $ | 2,000
Floating rate notes due 2020 |  |  | 1,000
3.35% senior notes due 2021 |  |  | 3,000
Floating rate notes due 2021 |  |  | 1,000
3.7% senior notes due 2023 |  |  | 6,000
4.1% senior notes due 2025 |  |  | 5,000
4.3% senior notes due 2028 |  |  | 9,000
4.78% senior notes due 2038 |  |  | 5,000
5.05% senior notes due 2048 |  |  | 8,000
Total debt principal |  | $ | 40,000

The Notes pay interest semi-annually and contain redemption terms which allow or require the Company to redeem the Notes at a defined redemption price plus accrued and unpaid interest at the redemption date. The net proceeds of the Notes will be used to fund the proposed acquisition of Aetna, discussed in “Note 2 Proposed Acquisition of Aetna” to our condensed consolidated financial statements.

If the proposed acquisition of Aetna has not been completed by September 3, 2019 (the “Outside Date”) or if, prior to such date, the merger agreement is terminated or the Company otherwise publicly announces that the merger will not be consummated, then the Company will be required to redeem all outstanding 2020 Floating Rate Notes, 2021 Floating Rate Notes, 2020 Notes, 2021 Notes, 2023 Notes, 2025 Notes, 2028 Notes and 2038 Notes at a redemption price equal to 101% of the aggregate principal amount of those notes plus accrued and unpaid interest. The 2048 Notes are not subject to this mandatory redemption provision. The proposed acquisition of Aetna is expected to close in the fourth quarter of 2018. The Company believes it has sufficient cash on hand and borrowing capacity to complete the transaction.

On December 3, 2017, in connection with the proposed acquisition of Aetna, the Company entered into a $49.0 billion unsecured bridge loan facility commitment. The Company paid approximately $221 million in fees upon entering into the agreement. The fees were capitalized in other current assets and are being amortized as interest expense over the period the bridge loan facility commitment is outstanding. The bridge loan facility commitment was reduced to $44.0 billion on December 15, 2017 upon the Company entering into a $5.0 billion term loan agreement. As discussed above, on March 9, 2018, the Company issued unsecured senior notes with an aggregate principal of $40.0 billion. At this time, the bridge loan facility commitment was reduced to $4.0 billion and the Company paid approximately $8 million in fees to retain the bridge loan facility commitment through the date of the proposed acquisition of Aetna. These fees were capitalized in other current assets and are being amortized as interest expense over the period the bridge loan facility commitment is outstanding. The Company recorded $2 million and $171 million of amortization of the bridge loan facility commitment fees during the three and nine months ended September 30, 2018, respectively, which was recorded

44

Table of Contents

in “Interest expense, net” on the condensed consolidated statements of operations. On October 26, 2018, the Company entered into a $4.0 billion unsecured 364-day bridge term loan agreement to formalize the bridge loan facility discussed above.

Our back‑up credit facilities, unsecured senior notes, and term loan agreement contain customary restrictive financial and operating covenants. These covenants do not include a requirement for the acceleration of our debt maturities in the event of a downgrade in our credit rating. We do not believe the restrictions contained in these covenants materially affect our financial or operating flexibility. As of September 30, 2018, the Company is in compliance with all debt covenants.

As of September 30, 2018, our long-term debt was rated “Baa1” by Moody’s and “BBB” by Standard & Poor’s, and our commercial paper program was rated “P‑2” by Moody’s and “A‑2” by Standard & Poor’s. In December 2017, subsequent to the announcement of the proposed acquisition of Aetna, Moody’s changed the outlook on our long-term debt to “Under Review” from “Stable.” Similarly, S&P placed our-long-term debt outlook on “Watch Negative” from “Stable”. Upon the issuance of the Notes on March 9, 2018, Standard and Poor’s lowered its corporate credit rating on our long-term debt to “BBB” from “BBB+” and changed the outlook from “Watch Negative” to “Stable”. In assessing our credit strength, we believe that both Moody’s and Standard & Poor’s considered, among other things, our capital structure and financial policies as well as our consolidated balance sheet, our historical acquisition activity and other financial information. Although we currently believe our long-term debt ratings will remain investment grade, we cannot guarantee the future actions of Moody’s and/or Standard & Poor’s. Our debt ratings have a direct impact on our future borrowing costs, access to capital markets and new store operating lease costs.

Off-Balance Sheet Arrangements

In connection with executing operating leases, we provide a guarantee of the lease payments. We also finance a portion of our new store development through sale-leaseback transactions, which involve selling stores to unrelated parties and then leasing the stores back under leases that generally qualify and are accounted for as operating leases. We do not have any retained or contingent interests in the stores, and we do not provide any guarantees, other than a guarantee of the lease payments, in connection with the transactions. In accordance with GAAP, such operating leases are not reflected in our condensed consolidated balance sheet. See “Note 11 – Commitments and Contingencies” to the condensed consolidated financial statements for a detailed discussion of these guarantees.

Critical Accounting Policies

We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which requires management to make certain estimates and apply judgment. We base our estimates and judgments on historical experience, current trends and other factors that management believes to be important at the time the condensed consolidated financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our condensed consolidated financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our condensed consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

Revenue Recognition

Effective January 1, 2018, we adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08, Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net), which amends the principal-versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, Identifying Performance Obligations and Licensing, which amends the guidance in those areas in the new revenue recognition standard. See the Adoption of New Revenue Recognition Standard section of “Note 1 - Accounting Policies” to the condensed consolidated financial statements for a detailed discussion of the adoption of this new revenue recognition standard.

45

Table of Contents

Goodwill

As discussed in “Note 3 – Goodwill and Intangible Assets” to the condensed consolidated financial statements, during 2018, our LTC reporting unit has continued to experience challenges that have impacted management’s ability to grow the business at the rate that was originally estimated when we made the acquisition of Omnicare, Inc. and when the prior year annual goodwill impairment test was performed. These challenges include lower client retention rates, lower occupancy rates in skilled nursing facilities, the deteriorating financial health of numerous skilled nursing facility customers, and continued facility reimbursement pressures. In June 2018, management submitted its initial budget for 2019 and updated the 2018 annual forecast which showed a deterioration in the financial results for the remainder of 2018 and in 2019, which also caused management to update its long term forecast beyond 2019. Based on these updated projections, we determined that there were indicators that the LTC reporting unit’s goodwill may be impaired, and accordingly, we performed an interim goodwill impairment test as of June 30, 2018. The results of the impairment test showed that the fair value of the LTC reporting unit was lower than the carrying value, resulting in a $3.9 billion pre-tax goodwill impairment charge in the second quarter of 2018. In addition to the lower financial projections, higher risk-free interest rates and lower market multiples of the peer group companies contributed to the amount of the goodwill impairment charge.

During the third quarter of 2018, we performed our required annual impairment tests of goodwill. The results of the impairment tests indicated that there was no impairment of goodwill. The goodwill impairment tests resulted in the fair values of our Pharmacy Services and Retail Pharmacy reporting units exceeding their carrying values by significant margins. The fair value of our LTC reporting unit exceeded its carrying value by approximately 2%. As of September 30, 2018, the goodwill balance in our LTC reporting unit is approximately $2.7 billion.

The fair value of our reporting units is estimated using a combination of a discounted cash flow method and a market multiple method. The determination of the fair value of our reporting units requires us to make significant assumptions and estimates. These assumptions and estimates primarily include, but are not limited to, the selection of appropriate peer group companies; control premiums and valuation multiples appropriate for acquisitions in the industries in which we compete; discount rates, terminal growth rates; and forecasts of revenue, operating profit, depreciation and amortization, income taxes, capital expenditures and future working capital requirements. When determining these assumptions and preparing these estimates, we consider each reporting unit’s historical results and current operating trends and our consolidated revenues, profitability and cash flow results, forecasts and industry trends. Our estimates can be affected by a number of factors including, but not limited to general economic and regulatory conditions, the risk-free interest rate environment, our market capitalization, efforts of customers and payers to reduce costs including their prescription drug costs and/or increase member co-payments, the continued efforts of competitors to gain market share, and consumer spending patterns.

Though we believe the financial projections used to determine the fair value of the LTC reporting unit in the third quarter of 2018 are reasonable and achievable, our LTC reporting unit may continue to face challenges that may affect our ability to grow the business at the rate we estimated when we performed such goodwill impairment test. These challenges and some of the key assumptions included in our financial projections to determine the estimated fair value of our LTC reporting unit include client retention rates, occupancy rates in skilled nursing facilities, the financial health of skilled nursing facility customers, facility reimbursement pressures, our ability to execute our senior living initiative, our ability to make acquisitions and integrate those businesses into our LTC operations in an orderly manner, as well as our ability to extract cost savings from labor productivity and other initiatives. We recently made a number of additions and changes to our LTC management team to better respond to these challenges. The estimated fair value of our LTC reporting unit is also dependent on earnings multiples of market participants in the pharmacy industry, as well as the risk-free interest rate environment which impacts the discount rate used in the discounted cash flow method. If we do not achieve our forecasts, given that the fair value of the LTC reporting unit only exceeded its carrying value by approximately 2% in the third quarter of 2018, it is reasonably possible in the near term that the goodwill of the LTC reporting unit could be deemed to be impaired again by a material amount.

For a full description of our other critical accounting policies, please refer to Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2017 Form 10 K.

46

Table of Contents

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the “Reform Act”) provides a safe harbor for forward-looking statements made by or on behalf of the Company. In addition, the Company and its representatives may, from time to time, make written or verbal forward-looking statements, including statements contained in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”) and in its reports to stockholders, press releases, webcasts, conference calls, meetings and other communications. Generally, the inclusion of the words “believe,” “expect,” “intend,” “estimate,” “project,” “anticipate,” “will,” “should” and similar expressions identify statements that constitute forward-looking statements. All statements addressing operating performance of CVS Health Corporation or any subsidiary, events or developments that the Company expects or anticipates will occur in the future, including statements relating to corporate strategy; revenue growth; earnings or earnings per common share growth; adjusted earnings or adjusted earnings per common share growth; free cash flow; debt ratings; inventory levels; inventory turn and loss rates; store development; relocations and new market entries; retail pharmacy business, sales trends and operations; PBM business, sales trends and operations; specialty pharmacy business, sales trends and operations; LTC pharmacy business, sales trends and operations; the Company’s ability to attract or retain customers and clients; pending acquisitions, including the proposed acquisition of Aetna; Medicare Part D competitive bidding, enrollment and operations; new product development; and the impact of industry and regulatory developments, as well as statements expressing optimism or pessimism about future operating results or events, are forward-looking statements within the meaning of the Reform Act.

The forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our SEC filings, including those set forth in the Risk Factors section within the 2017 Annual Report on Form 10-K, and including, but not limited to:

| · |  | Risks relating to the health of the economy in general and in the markets we serve, which could impact consumer purchasing power, preferences and/or spending patterns, drug utilization trends, the financial health of our PBM and LTC clients, retail and specialty pharmacy payors or other payors doing business with the Company and our ability to secure necessary financing, suitable store locations and sale-leaseback transactions on acceptable terms.

| · |  | Efforts to reduce reimbursement levels and alter health care financing practices, including pressure to reduce reimbursement levels for generic drugs.

| · |  | The possibility of PBM and LTC client loss and/or the failure to win new PBM and LTC business, including as a result of failure to win renewal of expiring contracts, contract termination rights that may permit clients to terminate a contract prior to expiration and early or periodic renegotiation of pricing by clients prior to expiration of a contract.

| · |  | The possibility of loss of Medicare Part D business and/or failure to obtain new Medicare Part D business, whether as a result of the annual Medicare Part D competitive bidding process or otherwise.

| · |  | Risks related to the frequency and rate of the introduction of generic drugs and brand name prescription products.

| · |  | Risks of declining gross margins attributable to increased competitive pressures, increased client demand for lower prices, enhanced service offerings and/or higher service levels and market dynamics and, with respect to the PBM industry, regulatory changes that impact our ability to offer plan sponsors pricing that includes the use of retail “differential” or “spread” or the use of maximum allowable cost pricing.

| · |  | Regulatory changes, business changes and compliance requirements and restrictions that may be imposed by Centers for Medicare and Medicaid Services (“CMS”), Office of Inspector General or other government

47

Table of Contents

agencies relating to the Company’s participation in Medicare, Medicaid and other federal and state government-funded programs, including sanctions and remedial actions that may be imposed by CMS on our Medicare Part D business.

| · |  | Risks and uncertainties related to the timing and scope of reimbursement from Medicare, Medicaid and other government-funded programs, including the possible impact of sequestration, the impact of other federal budget, debt and deficit negotiations and legislation that could delay or reduce reimbursement from such programs and the impact of any closure, suspension or other changes affecting federal or state government funding or operations.

| · |  | Possible changes in industry pricing benchmarks used to establish pricing in many of our PBM and LTC client contracts, pharmaceutical purchasing arrangements, retail network contracts, specialty payor agreements and other third party payor contracts.

| · |  | Efforts to increase reimbursement rates in PBM pharmacy networks and to inhibit the ability of PBMs to audit network pharmacies for fraud, waste and abuse.

| · |  | Risks related to increasing oversight of PBM activities by state departments of insurance and boards of pharmacy.

| · |  | A highly competitive business environment, including the uncertain impact of increased consolidation in the PBM industry, the possibility of combinations, joint ventures or other collaboration between PBMs and retailers, uncertainty concerning the ability of our retail pharmacy business to secure and maintain contractual relationships with PBMs and other payors on acceptable terms, uncertainty concerning the ability of our PBM business to secure and maintain competitive access, pricing and other contract terms from retail network pharmacies in an environment where some PBM clients are willing to consider adopting narrow or more restricted retail pharmacy networks, the possibility of our retail stores or specialty pharmacies being excluded from narrow or restricted networks, the potential of disruptive innovation from existing and new competitors and risks related to developing and maintaining a relevant experience for our customers.

| · |  | The Company’s ability to timely identify or effectively respond to changing consumer preferences and spending patterns, an inability to expand the products being purchased by our customers, or the failure or inability to obtain or offer particular categories of products.

| · |  | Risks relating to our ability to secure timely and sufficient access to the products we sell from our domestic and/or international suppliers, including limited distribution drugs.

| · |  | Reform of the U.S. health care system, including ongoing implementation of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, “ACA”) and the possible repeal and replacement of all or parts of ACA, continuing legislative efforts, regulatory changes and judicial interpretations impacting our health care system and the possibility of shifting political and legislative priorities related to reform of the health care system in the future.

| · |  | Risks related to changes in legislation, regulation and government policy (including through the use of Executive Orders) that could significantly impact our business and the health care and retail industries, including, but not limited to, the possibility of major developments in tax policy or trade relations, such as the imposition of unilateral tariffs on imported products, changes with respect to the approval process for biosimilars, or changes or developments with respect to the regulation of drug pricing, including federal and state drug pricing programs.

| · |  | Risks relating to any failure to properly maintain and protect our information technology systems, our information security systems, our infrastructure to support our business and the privacy and security of sensitive customer and business information, including from external intrusions and threats.

| · |  | Risks related to compliance with a broad and complex regulatory framework, including compliance with new and existing federal, state and local laws and regulations relating to health care, network pharmacy

48

Table of Contents

reimbursement and auditing, accounting standards, corporate securities, tax, environmental and other laws and regulations affecting our business.

| · |  | Risks related to litigation, government investigations and other legal proceedings as they relate to our business, the pharmacy services, retail pharmacy, LTC pharmacy, specialty pharmacy or retail clinic industries, or to the health care industry generally.

| · |  | The risk that any condition related to the closing of any proposed acquisition, including the proposed acquisition of Aetna, may not be satisfied on a timely basis or at all, including the inability to obtain required regulatory approvals of any proposed acquisition, including the proposed acquisition of Aetna, or on the terms desired or anticipated; the risk that such approvals may result in the imposition of conditions that could adversely affect the resulting combined company or the expected benefits of any proposed transaction, including the proposed acquisition of Aetna; and the risk that the proposed transactions, including the proposed acquisition of Aetna fail to close for any other reason, which could negatively impact our stock price and our future business and financial results.

| · |  | The possibility that the anticipated synergies and other benefits from any acquisition by us, including the proposed acquisition of Aetna, will not be realized, or will not be realized within the expected time periods.

| · |  | Other risks related to the proposed acquisition of Aetna including the possibility of failing to retain existing management including key executives of Aetna, the potential for disruption of our business relationships due to uncertainty associated with the proposed acquisition of Aetna, the increased difficulty for us to pursue alternatives to the proposed acquisition of Aetna, and the possibility that the proposed acquisition of Aetna may not be accretive to our earnings per share.

| · |  | The risks and uncertainties related to our ability to integrate the operations, products, services and employees of any entities acquired by us, including the proposed acquisition of Aetna and the effect of the potential disruption of management’s attention from ongoing business operations due to any pending acquisitions, including the proposed acquisition of Aetna.

| · |  | The accessibility or availability of adequate financing on a timely basis and on reasonable terms and the risks related to the indebtedness incurred to fund the proposed acquisition of Aetna.

| · |  | Risks related to the outcome of any legal proceedings related to, or involving any entity that is a part of, any proposed acquisition contemplated by us, including the risk that we may be subject to securities class action and derivative lawsuits in connection with the proposed acquisition of Aetna.

| · |  | The possibility of lower than expected valuations at the Company’s reporting units could result in goodwill impairment charges at those reporting units.

| · |  | Other risks and uncertainties detailed from time to time in our filings with the SEC.

The foregoing list is not exhaustive. There can be no assurance that the Company has correctly identified and appropriately assessed all factors affecting its business. Additional risks and uncertainties not presently known to the Company or that it currently believes to be immaterial also may adversely impact the Company. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the Company’s business, financial condition and results of operations. For these reasons, you are cautioned not to place undue reliance on the Company’s forward-looking statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As of September 30, 2018, the Company did not have any interest rate, foreign currency exchange rate or commodity derivative instruments in place and believes that as of September 30, 2018 its exposure to interest rate risk (inherent in the Company’s debt portfolio), foreign currency exchange rate risk and commodity price risk is not material.

49

Table of Contents

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures: The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a‑15(f) and 15d‑15(f)) as of September 30, 2018, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to provide reasonable assurance that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

Changes in internal control over financial reporting: There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a‑15 or Rule 15d‑15 that occurred in the three months ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

50

Table of Contents

Part II

Item 1. Legal Proceedings

I. Legal Proceedings

We refer you to “Note 11 - Commitments and Contingencies” contained in the “Notes to the Condensed Consolidated Financial Statements” of our Quarterly Report on Form 10‑Q for the three and nine months ended September 30, 2018 for a description of our legal proceedings.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended September 30, 2018, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2016 Repurchase Program. See “Note 5 - Share Repurchase Programs” contained in the “Notes to the Condensed Consolidated Financial Statements” of our Quarterly Report on Form 10‑Q for the three months ended September 30, 2018.

|  |  |  |  |  |  |  |  | Approximate Dollar
|  |  |  |  |  |  | Total Number of Shares |  | Value of Shares that
|  | Total Number |  | Average |  | Purchased as Part of |  | May Yet Be
|  | of Shares |  | Price Paid per |  | Publicly Announced |  | Purchased Under the
Fiscal Period |  | Purchased |  | Share |  | Plans or Programs |  | Plans or Programs
July 1, 2018 through July 31, 2018 |  | — |  | $ | — |  | — |  | $ | 13,869,392,446
August 1, 2018 through August 30, 2018 |  | — |  | $ | — |  | — |  | $ | 13,869,392,446
September 1, 2018 through September 30, 2018 |  | — |  | $ | — |  | — |  | $ | 13,869,392,446
|  | — |  |  |  |  | — |  |  |

51

Table of Contents

Item 6. Exhibits

Exhibits:

Exhibits marked with an asterisk (*) are hereby incorporated by reference to exhibits or appendices previously filed by the Registrant as indicated in brackets following the description of the exhibit.

3.1* | Restated Certificate of Incorporation of the Registrant [incorporated by reference to Exhibit 3.1C to the Registrant’s Current Report on Form 8‑K dated June 5, 2018 (Commission File No. 001‑01011)].
3.2* | By‑laws of Registrant, as amended and restated [incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8‑K dated June 5, 2018 (Commission File No. 001‑01011)].
10.1 | Confidential Separation Agreement between the Registrant and the Registrant’s Executive Vice President and Chief Financial Officer effective as of June 25, 2018.
15.1 | Letter re: Unaudited Interim Financial Information.
31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101 | The following materials from the CVS Health Corporation Quarterly Report on Form 10‑Q for the three and nine months ended September 30, 2018 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Operations, (ii) the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flows and (v) related Footnotes to the Condensed Consolidated Financial Statements.

52

Table of Contents

Signatures:

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10‑Q to be signed on its behalf by the undersigned, thereunto duly authorized.

CVS Health Corporation |
(Registrant) |
/s/ David M. Denton |
David M. Denton |
Executive Vice President and Chief Financial Officer |
November 6, 2018 |

53